<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002123" GROUP_ID="MENSTR" ID="808599081315332922" MERGED_FROM="" MODIFIED="2009-08-10 04:36:27 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Short title (no longer in use): Dysmenorrhoea: TENS and acupuncture: Pain&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-08-10 14:34:02 +1200" NOTES_MODIFIED_BY="jane clarke" REVIEW_NO="MW 525" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2009-08-10 04:36:27 +0200" MODIFIED_BY="Jane Clarke">
<TITLE MODIFIED="2008-09-08 16:48:10 +1200" MODIFIED_BY="Liz Dooley">Transcutaneous electrical nerve stimulation for primary dysmenorrhoea</TITLE>
<CONTACT MODIFIED="2009-08-10 04:36:27 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="17383" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xiaoshu</FIRST_NAME><LAST_NAME>Zhu</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>x.zhu@uws.edu.au</EMAIL_1><EMAIL_2>mszhuxiaoshu@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Center for Complementary Medicine Research</DEPARTMENT><ORGANISATION>School of Biomedical and Health Science, University of Western Sydney</ORGANISATION><ADDRESS_1>Building 24, Campbelltown Campus, Locked Bag 1797</ADDRESS_1><ADDRESS_2>Penrith South DC</ADDRESS_2><CITY>Sydney</CITY><ZIP>1797</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 2 4620 3338</PHONE_1><FAX_1>61 2 4620 3792</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-10 04:36:27 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="10564" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Michelle</FIRST_NAME><LAST_NAME>Proctor</LAST_NAME><POSITION>Editor, Cochrane Menstrual Disorders and Subfertility Group</POSITION><EMAIL_1>michelleproctor@clear.net.nz</EMAIL_1><EMAIL_2>michelle.proctor@corrections.govt.nz</EMAIL_2><URL>research/cochrane</URL><ADDRESS><DEPARTMENT>Psychological Service</DEPARTMENT><ORGANISATION>Department of Corrections</ORGANISATION><ADDRESS_1>PO Box 302457</ADDRESS_1><ADDRESS_2>North Harbour</ADDRESS_2><CITY>Auckland</CITY><ZIP>1310</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9448 3208</PHONE_1><FAX_1>+64 9 3035969</FAX_1></ADDRESS></PERSON><PERSON ID="9CE26E7F82E26AA200CD32E53036321F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cindy</FIRST_NAME><LAST_NAME>Farquhar</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>c.farquhar@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>FMHS Park Road</ADDRESS_1><ADDRESS_2>Grafton</ADDRESS_2><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 6309943</PHONE_1><FAX_1>+64 9 6309858</FAX_1></ADDRESS></PERSON><PERSON ID="14625" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Will</FIRST_NAME><LAST_NAME>Stones</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>william.stones@aku.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>The Aga Khan University</ORGANISATION><ADDRESS_1>PO Box 30270-00100 GPO</ADDRESS_1><CITY>Nairobi</CITY><ZIP>SO16 5YA</ZIP><COUNTRY CODE="KE">Kenya</COUNTRY></ADDRESS></PERSON><PERSON ID="18166" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lin</FIRST_NAME><LAST_NAME>He</LAST_NAME><POSITION>Information Support</POSITION><EMAIL_1>helin4467@sina.com</EMAIL_1><EMAIL_2>he_32@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Books &amp; Information Centre</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37 Guoxue Lane</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610064</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2275</PHONE_1><FAX_1>+86 28 8542 2277</FAX_1></ADDRESS></PERSON><PERSON ID="17383" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xiaoshu</FIRST_NAME><LAST_NAME>Zhu</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>x.zhu@uws.edu.au</EMAIL_1><EMAIL_2>mszhuxiaoshu@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Center for Complementary Medicine Research</DEPARTMENT><ORGANISATION>School of Biomedical and Health Science, University of Western Sydney</ORGANISATION><ADDRESS_1>Building 24, Campbelltown Campus, Locked Bag 1797</ADDRESS_1><ADDRESS_2>Penrith South DC</ADDRESS_2><CITY>Sydney</CITY><ZIP>1797</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 2 4620 3338</PHONE_1><FAX_1>61 2 4620 3792</FAX_1></ADDRESS></PERSON><PERSON ID="6034200E82E26AA200991D564912EB85" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julie</FIRST_NAME><LAST_NAME>Brown</LAST_NAME><POSITION>Cochrane Sytematic Reviewer</POSITION><EMAIL_1>j.brown@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>FMHS</ADDRESS_1><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 3737599</PHONE_1><FAX_1>+64 9 3035969</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-05-04 11:56:51 +1200" MODIFIED_BY="Julie A Brown" NOTES="&lt;p&gt;Minor update: 2/28/01&lt;/p&gt;" NOTES_MODIFIED="2009-05-04 11:56:51 +1200" NOTES_MODIFIED_BY="Julie A Brown">
<UP_TO_DATE>
<DATE DAY="3" MONTH="5" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="4" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2009-08-10 14:22:11 +1200" MODIFIED_BY="jane clarke">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2009-08-10 14:22:11 +1200" MODIFIED_BY="jane clarke">
<DATE DAY="10" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>No new trials were identified </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-10 14:21:29 +1200" MODIFIED_BY="jane clarke">
<DATE DAY="5" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>This review has now been updated. No new trials were identified. Risk of bias tables have been added and the trial has been formatted as per Cochrane guidelines. An earlier version of the review included acupuncture but at the time of updating the review was split into two reviews, one of TENS and one of acupuncture. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-05-05 13:15:32 +1200" MODIFIED_BY="Julie A Brown">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-05 13:15:32 +1200" MODIFIED_BY="Julie A Brown">
<DATE DAY="19" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>This published review: Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. <I>Cochrane Database of Systematic Reviews</I> 2002, Issue 1, has now been divided into two reviews 'Transcutaneous electrical nerve stimulation for primary dysmenorrhoea' and 'Acupuncture for primary dysmenorrhoea'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-05 13:15:28 +1200" MODIFIED_BY="Julie A Brown">
<DATE DAY="16" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="11" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Auckland, School of Medicine, Auckland</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Princess of Wales Memorial Trust Fund administered by the Mercia Barnes Fund</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-10 14:34:02 +1200" MODIFIED_BY="jane clarke">
<SUMMARY MODIFIED="2009-07-14 11:53:15 +1200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-05-04 13:20:21 +1200" MODIFIED_BY="Julie A Brown">Transcutaneous electrical nerve stimulation for primary dysmenorrhoea</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-14 11:53:15 +1200" MODIFIED_BY="[Empty name]">
<P>High-frequency nerve stimulation may help relieve painful menstrual cramps. Dysmenorrhoea is a very common complaint that refers to painful menstrual cramps in the uterus. Transcutaneous electrical nerve stimulation (TENS) involves the sending of an electric current by placing electrodes on the skin to stimulate the nerves and reduce pain. It is thought to alter the body's ability to receive and understand pain signals rather than by having a direct effect on the uterine contractions. The review of trials found that high-frequency TENS may help but there is not enough evidence to assess the effect of low-frequency TENS. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-14 11:51:55 +1200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-07-13 22:43:23 +1200" MODIFIED_BY="[Empty name]">
<P>Medical therapy for dysmenorrhoea (painful menstrual cramps of the uterus) such as non-steroidal anti-inflammatory drugs or the oral contraceptive pill work by reducing myometrial (uterine muscle) activity. Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacological intervention shown to be effective for pain relief in a variety of conditions. TENS may be able to alter the body's ability to receive and perceive pain signals rather than having a direct effect on uterine contractions.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-07-13 22:54:41 +1200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of high and low-frequency TENS when compared to placebo, no treatment, or medical treatment for primary dysmenorrhoea.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-14 11:50:08 +1200" MODIFIED_BY="[Empty name]">
<P>Electronic searches of the Cochrane Menstrual Disorders and Subfertility Group Register of controlled trials, <I>The Cochrane Library</I> (Issue 1, 2009), MEDLINE, EMBASE, CINAHL, and AMED were performed (updated April 2009) to identify relevant randomised controlled trials. The Cochrane Complementary Medicine Field Register of controlled trials (CISCOM) was also searched. Attempts were also made to identify trials from the UK National Research Register, the Clinical Trial Register, and the citation lists of review articles and included trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-14 11:49:29 +1200" MODIFIED_BY="[Empty name]">
<P>The inclusion criteria were: randomised controlled trials (RCTs) of TENS compared to placebo, no treatment, or medical treatment for primary dysmenorrhoea. Exclusion criteria were: mild, infrequent, or secondary dysmenorrhoea and dysmenorrhoea associated with an intrauterine device (IUD).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-14 11:51:04 +1200" MODIFIED_BY="[Empty name]">
<P>Seven RCTs were identified that fulfilled the inclusion criteria for this review. No new studies were identified in the update. Quality assessment and data extraction were performed independently by two review authors. Data unsuitable for meta-analysis were reported as descriptive data and were included for discussion. The outcome measures were pain relief (dichotomous, visual analogue scale, descriptive), adverse effects, use of analgesics additional to treatment, and absence from work or school.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-14 11:51:55 +1200" MODIFIED_BY="[Empty name]">
<P>Overall, high-frequency TENS was shown to be more effective for pain relief than placebo TENS (OR 7.2, 95% CI 3.1 to 16.5). Low-frequency TENS was found to be no more effective in reducing pain than placebo TENS (OR 1.48, 95% CI 0.43 to 5.08). There were conflicting results regarding whether high-frequency TENS was more effective than low-frequency TENS.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-13 22:57:08 +1200" MODIFIED_BY="[Empty name]">
<P>High-frequency TENS was found to be effective for the treatment of dysmenorrhoea by a number of small trials. The minor adverse effects reported in one trial require further investigation. There is insufficient evidence to determine the effectiveness of low-frequency TENS in reducing dysmenorrhoea.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-10 14:34:02 +1200" MODIFIED_BY="jane clarke">
<BACKGROUND MODIFIED="2009-07-14 12:03:13 +1200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-07-14 11:56:24 +1200" MODIFIED_BY="[Empty name]">
<P>Dysmenorrhoea refers to the occurrence of painful menstrual cramps of uterine origin. It is a common gynaecological complaint that can affect as many as 50% of women; 10% of these women suffer severely enough to render them incapacitated for one to three days each menstrual cycle (<LINK REF="REF-Dawood-1990b" TYPE="REFERENCE">Dawood 1990b</LINK>). This has a significant impact on personal health and it also has a global economic impact. In the USA alone, it is estimated that annual losses are 600 million work hours and two billion dollars (<LINK REF="REF-Dawood-1984" TYPE="REFERENCE">Dawood 1984</LINK>).</P>
<P>Dysmenorrhoea is commonly defined within two subcategories. When the pelvic pain is associated with an identifiable pathological condition, such as endometriosis, it is considered to be secondary dysmenorrhoea. In contrast, menstrual pain without organic pathology is called primary dysmenorrhoea (<LINK REF="REF-Lichten-1987" TYPE="REFERENCE">Lichten 1987</LINK>).</P>
<P>The initial onset of primary dysmenorrhoea is usually at or shortly (six to 12 months) after menarche (the commencement of menstrual periods), when ovulatory cycles are established. The pain duration is commonly 48 to 72 hours and is associated with the menstrual flow. In contrast, secondary dysmenorrhoea is more likely to occur years after the onset of menarche and occurs premenstrually as well as during menstruation. This distinction is not necessarily robust however as severe primary dysmenorrhoea in young women may indicate endometriosis (<LINK REF="REF-Punnonen-1980" TYPE="REFERENCE">Punnonen 1980</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-07-14 11:59:14 +1200" MODIFIED_BY="[Empty name]">
<P>Dysmenorrhoea is commonly treated with non-steroidal anti-inflammatory drugs (NSAIDs) or oral contraceptive pills (OCPs), both of which work by reducing myometrial (uterine muscle) activity. However, these treatments are accompanied by a number of adverse effects making an effective non-pharmacological method of treating dysmenorrhoea of great potential value.</P>
<P>Transcutaneous electrical nerve stimulation (TENS) involves stimulation of the skin using electrical currents at various pulse rates (frequencies) and intensities in order to provide pain relief. Since the late 19th century, TENS has been used to treat many conditions, such as acne, abscesses, corns, cramps, gout and impotence (<LINK REF="REF-Sheon-1984" TYPE="REFERENCE">Sheon 1984</LINK>). It is also currently used to manage pain from contractions during labour (<LINK REF="REF-Carroll-1997" TYPE="REFERENCE">Carroll 1997</LINK>).</P>
<P>TENS machines are portable and can be used in a home situation as well as a clinical setting. Modern day TENS can be divided into two subcategories, high and low frequency. Low-frequency TENS (also referred to as acupuncture-like TENS) usually consists of pulses delivered at between 1 Hz to 4 Hz, at high intensity and long pulse width so they evoke visible muscle contractions. High-frequency TENS (conventional TENS) usually consists of pulses delivered at between 50 Hz and 120 Hz, at a low intensity (<LINK REF="REF-Kaplan-1997" TYPE="REFERENCE">Kaplan 1997</LINK>; <LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2009-07-14 12:02:44 +1200" MODIFIED_BY="[Empty name]">
<P>In dysmenorrhoea, TENS seems to work by alteration of the body's ability to receive or perceive pain signals rather than by having a direct effect on the uterine contractions (<LINK REF="REF-Smith-1991" TYPE="REFERENCE">Smith 1991</LINK>). The electrodes can be placed on traditional acupuncture sites or at the site of the pain. This modality has been stated to be effective for pain relief in a variety of conditions (<LINK REF="REF-Gersh-1985" TYPE="REFERENCE">Gersh 1985</LINK>) but more recent systematic reviews have established that TENS is ineffective for postoperative pain (<LINK REF="REF-Carroll-1996" TYPE="REFERENCE">Carroll 1996</LINK>) and labour pain (<LINK REF="REF-Carroll-1997" TYPE="REFERENCE">Carroll 1997</LINK>). Evidence for the efficacy of TENS in chronic pain conditions is limited (<LINK REF="REF-McQuay-1998" TYPE="REFERENCE">McQuay 1998</LINK>) although a systematic review indicates benefit for pain associated with knee osteoarthritis (<LINK REF="REF-Osiri-2001" TYPE="REFERENCE">Osiri 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-07-14 12:03:13 +1200" MODIFIED_BY="[Empty name]">
<P>Consumers generally perceive complementary medicine to be more natural than conventional medicine and have fewer concerns about side effects. If pain relief can be brought about through non-pharmacological means then this may be of benefit to both the consumer and healthcare providers.</P>
<P>
<BR/>
</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-13 23:08:27 +1200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of high and low-frequency TENS compared to placebo, no treatment, or medical treatment for primary dysmenorrhoea.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-07-14 12:29:40 +1200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-14 12:05:39 +1200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-06-16 11:28:35 +1200" MODIFIED_BY="Julie A Brown">
<P>All prospective randomised controlled trials comparing TENS to placebo, no treatment, or medical treatment for the treatment of primary dysmenorrhoea. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-14 12:04:08 +1200" MODIFIED_BY="[Empty name]">
<P>Participants in the trials had to meet all the following inclusion criteria for the trial to be included in the review.</P>
<P>Inclusion criteria:</P>
<UL>
<LI>women of reproductive age;</LI>
<LI>women with moderate to severe primary dysmenorrhoea (severe or incapacitating pain for at least one day of menses);</LI>
<LI>women affected by dysmenorrhoea in &gt; 50% of their menstrual cycles.</LI>
</UL>
<P>If participants in the trial meet any of the following exclusion criteria the trial was not included in the review.</P>
<P>Exclusion criteria:</P>
<UL>
<LI>women with secondary dysmenorrhoea (i.e. associated with identifiable pelvic pathology);</LI>
<LI>women with dysmenorrhoea due to the presence of an intrauterine device (IUD);</LI>
<LI>women with mild or infrequent dysmenorrhoea.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-14 12:05:39 +1200" MODIFIED_BY="[Empty name]">
<P>The specific interventions to be considered were as follows.</P>
<P>1. High-frequency TENS versus placebo or no treatment for primary dysmenorrhoea.<BR/>2. Low-frequency TENS versus placebo or no treatment for primary dysmenorrhoea.<BR/>3. High-frequency TENS versus low-frequency TENS for primary dysmenorrhoea.<BR/>4. High-frequency TENS versus acupuncture for primary dysmenorrhoea.<BR/>5. Low-frequency TENS versus acupuncture for primary dysmenorrhoea.<BR/>6. TENS versus other medical treatment for primary dysmenorrhoea.</P>
<P>Low-frequency TENS (acupuncture-like TENS) is defined as 1 Hz to 4 Hz pulses delivered at high intensity.<BR/>High-frequency TENS (conventional TENS) is defined as 50 Hz to 120 Hz pulses delivered at a low intensity.<BR/>Placebo TENS is when no electrical current is used, so the settings and amplitude do not produce any electrical stimulation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-13 23:18:06 +1200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-13 23:16:52 +1200" MODIFIED_BY="[Empty name]">
<P>Pain relief (measured either on a visual analogue scale (VAS), other scales, or a dichotomous scale)</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-13 23:18:06 +1200" MODIFIED_BY="[Empty name]">
<P>1. Adverse effects from treatment (incidence and types of side effects)<BR/>2. Requirements for additional medication (measured as a ratio for women requiring analgesics additional to their assigned treatment)<BR/>3. Restriction of daily life activities (measured as a ratio for women who report activity restriction)<BR/>4. Absence from work or school (measured as a ratio for women reporting absences from work or school)</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-14 12:08:51 +1200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-07-14 12:07:14 +1200" MODIFIED_BY="[Empty name]">
<P>All reports which described (or might describe) randomised controlled trials of TENS in the treatment of dysmenorrhoea were obtained using the following search strategies (April 2009). The Menstrual Disorders and Subfertility Group Specialised Register of controlled trials was searched for any trials with dysmenorrhoea or dysmenorrhoea in the title, abstract, or keyword sections; see the Review Group Module (<I>The Cochrane Library</I>) for more details on the makeup of the Specialised Register (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Other databases searched were: CENTRAL (<I>The Cochrane Library</I>) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), MEDLINE (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE ( <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), AMED (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), and PsycINFO (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-14 12:08:51 +1200" MODIFIED_BY="[Empty name]">
<P>The National Research Register (NRR), a register of ongoing and recently completed research projects funded by or of interest to the United Kingdom's National Health Service, as well as entries from the Medical Research Council's Clinical Trials Register and details on reviews in progress collected by the NHS Centre for Reviews and Dissemination were searched for any trials with dysmenorrhoea as a keyword. The Clinical Trials register, a registry of both federally and privately funded US clinical trials, was also searched for the same keyword.</P>
<P>The Cochrane Complementary Medicine Field Register of controlled trials (CISCOM) was searched for any trials with dysmenorrhoea in the title, abstract, or keyword fields. No additional trials were found.</P>
<P>A letter was written to the Chinese Cochrane Centre requesting information on any useful Chinese databases, however they were unable to help as they are a newly formed centre and are still under-resourced at present. We plan to re-contact them for future updates of this review.</P>
<P>The citation lists of relevant publications, review articles, included studies, and abstracts of scientific meetings were also searched.</P>
<P>Letters were sent to major investigators of TENS or acupuncture techniques and the authors of included studies to seek information on additional published or unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-07-14 12:29:40 +1200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-07-14 12:11:22 +1200" MODIFIED_BY="[Empty name]">
<P>One review author scanned the titles and abstracts of articles retrieved by the search and removed those that were clearly not relevant. The full text of potentially relevant articles were retrieved. The selection of trials for inclusion in the review was performed independently by two review authors (MW, CS). Where necessary, primary authors were contacted to provide additional information on patient eligibility criteria and methodologies. Any disagreements were resolved by discussion and consensus, or by a third author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-07-14 12:14:34 +1200" MODIFIED_BY="[Empty name]">
<P>Data were extracted from eligible studies using a data extraction form designed by the review authors. Where studies had multiple publications, the main trial report was used as the reference supplemented by additional details from secondary papers. The review authors corresponded with primary authors, where possible, to resolve any data queries.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-07-14 12:17:57 +1200" MODIFIED_BY="[Empty name]">
<P>The included studies were assessed for risk of bias. The Cochrane risk of bias assessment tool was used to assess:</P>
<UL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding;</LI>
<LI>completeness of the outcome data;</LI>
<LI>selective outcome reporting;</LI>
<LI>other potential sources of bias.</LI>
</UL>
<P>The selection of trials for inclusion in the original review was performed independently by the two review authors (MW, CS) after employing the search strategy described previously, and by MS and CF in the update (2009). The conclusions can be referred to in the 'Risk of bias' tables and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>Additional information on trial methodology, original trial data, or both were sought from the authors of the majority of trials. This additional information was sought by sending letters, e-mail, or both to the authors of all the trials except <LINK REF="STD-Santiesteban-1985" TYPE="STUDY">Santiesteban 1985</LINK> (no current contact details for the authors could be found). Replies were received from Prof Dawood from the <LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK> study, and D Lewers from the <LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK> study; both supplied extra information regarding trial methodology. As no response was received from the trial by <LINK REF="STD-Santiesteban-1985" TYPE="STUDY">Santiesteban 1985</LINK> the study has been moved to the studies awaiting classification until we are able to confirm the methodology.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-14 12:21:07 +1200" MODIFIED_BY="[Empty name]">
<P>Statistical analyses were performed in accordance with the guidelines for statistical analysis developed by the Cochrane Menstrual Disorders and Subfertility Group. Where possible, the outcomes were pooled statistically. For dichotomous data (for example, proportion of participants with a specific adverse side effect), results for each study were expressed as an odds ratio (OR) with 95% confidence interval (CI) and combined for meta-analysis with RevMan software using the Peto-modified Mantel-Haenszel method. Continuous differences between groups in the meta-analysis were shown as a mean difference (MD) and 95% CI. A fixed-effect model was used and heterogeneity between the results of different studies was examined by inspecting the scatter in the data points and the overlap in their CIs and more formally by checking the results of the Chi<SUP>2</SUP> tests. No significant heterogeneity was found among studies that were combined in the meta-analysis.</P>
<P>For a number of included studies we were not able to extract data that could be used in the meta-analysis. These data were included as descriptive data in 'other data' tables and can also be viewed in the 'Data and analyses' tables.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-07-14 12:24:56 +1200" MODIFIED_BY="[Empty name]">
<P>Four of the included studies were of crossover design (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>; <LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>; <LINK REF="STD-Milsom-1994" TYPE="STUDY">Milsom 1994</LINK>; <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>). Phase-one data (data prior to crossover) were not available for any of these trials. Crossover trials have been criticised for leading to invalid estimates of effect when the outcome measure used affects entry to subsequent phase of the trial (for example where pregnancy is the outcome of interest those becoming pregnant in phase one of the trial cannot be crossed over to the alternative treatment). In the case of this review, this problem is less of a concern as the main outcome measure is pain relief.</P>
<P>The only real concern is the potential for carryover effects of TENS from one menstrual cycle to another, which is likely to be minimal as all four crossover trials performed treatment during the menses only. Therefore, due to the small likelihood of bias, the small number of trials, and the minimal pooling of data in the meta-analysis, the results of the crossover trials were included in this review. The only instance where data from a parallel and crossover trial were pooled is for the outcome of overall experience of pain relief for low-frequency TENS versus placebo TENS. Both trials and the meta-analysis reported a non-significant result for this outcome and including or excluding the crossover data did not impact on this conclusion (<LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-14 12:25:16 +1200" MODIFIED_BY="[Empty name]">
<P>Data were analysed on an intention-to-treat basis, as far as possible, and attempts were made to obtain missing data from the primary investigators, where possible.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-07-14 12:27:03 +1200" MODIFIED_BY="[Empty name]">
<P>The review authors considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a meaningful summary. Statistical heterogeneity was assessed using the I<SUP>2</SUP> statistic. An I<SUP>2</SUP> &gt; 50% was taken to imply substantial heterogeneity and further exploration was undertaken using sensitivity analyses to explain this, if required.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-05-04 14:42:56 +1200" MODIFIED_BY="Julie A Brown">
<P>The review authors aimed to minimise the potential impact of reporting bias by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. A funnel plot was not possible due the limited number of studies included in the review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-14 12:27:43 +1200" MODIFIED_BY="[Empty name]">
<P>The data from the primary studies were combined using a fixed-effect model in the following comparisons.</P>
<OL>
<LI>High-frequency TENS versus placebo.</LI>
<LI>Low-frequency TENS versus placebo.</LI>
<LI>High-frequency TENS versus low-frequency TENS.</LI>
<LI>TENS versus medical treatment.</LI>
</OL>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-05-04 14:55:02 +1200" MODIFIED_BY="Julie A Brown">
<P>There was no planned subgroup analysis in this review.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-07-14 12:29:40 +1200" MODIFIED_BY="[Empty name]">
<P>In one trial, the mean pain relief figure reported in the trial (26.1) did not correlate with the reported scores for each participant that were also presented (46, 57, 60, 0, 0, 0, 41, 40, 1) (<LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>). The authors of the trial did not respond to correspondence, therefore the mean used in the meta-analysis was not that reported in the report but was recalculated from the individual scores that were also given (a mean of 27.2). A sensitivity analysis using both means showed that there was very little difference in the ORs they elicited.</P>
<SUBSECTION>
<HEADING LEVEL="4">Updating the review</HEADING>
<P>It is the intention of the review authors that a new search for RCTs will be carried out yearly and the review updated accordingly.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-10 14:34:02 +1200" MODIFIED_BY="jane clarke">
<STUDY_DESCRIPTION MODIFIED="2009-07-14 12:48:28 +1200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2009-07-13 23:36:23 +1200" MODIFIED_BY="[Empty name]">
<P>Nine randomised controlled trials were identified that involved TENS for the treatment of dysmenorrhoea. Seven of these trials were included in this review, one was excluded, and one is awaiting classification.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-14 12:48:28 +1200" MODIFIED_BY="[Empty name]">
<P>
<BR/>Three of the trials were of parallel design (<LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK>; <LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>; <LINK REF="STD-Neighbors-1987" TYPE="STUDY">Neighbors 1987</LINK>) and four used a crossover design (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>; <LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>; <LINK REF="STD-Milsom-1994" TYPE="STUDY">Milsom 1994</LINK>; <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>).</P>
<P>Five of the trials specified the inclusion of women with primary dysmenorrhoea only. Four of these trials performed some type of physical or gynaecological examination to confirm the diagnosis of 'no pathology'. Other common exclusion criteria were the use of oral contraceptives (OCPs) or an IUD. The range of ages of participants included in all the trials was 15 to 38 years.</P>
<P>Physical treatment regimens are particularly difficult to administer consistently and there are additional problems associated with the use of placebo or sham techniques. Summarised below are details on how the included trials dealt with treatment consistency and the use of placebo or sham therapies. For additional information on trial characteristics see the table 'Characteristics of included studies'. For a summary of the TENS modalities used, such as frequencies and pulse width, see TENS modalities (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>
<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK> (high-frequency TENS, placebo TENS, ibuprofen)<BR/>Women were treated with TENS for two cycles, placebo TENS for one cycle, and ibuprofen for one cycle; the treatment sequence was randomised. Portable TENS units were used and for high-frequency TENS the woman was able to adjust the amplitude to produce a comfortable tingling sensation or achieve satisfactory pain relief. The placebo TENS was set up in exactly the same way except the settings and amplitude did not produce any electrical stimulation. The participants and investigators were blinded to whether real or placebo TENS was being used, however for the ibuprofen cycle blinding was not possible. There was no information on how the investigators ensured that the TENS units were correctly used by the women, however daily logs were kept of the amount of TENS use per day.</P>
<P>
<LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK> (low-frequency TENS, placebo pill)<BR/>Women were randomly assigned to the experimental or control group. Both groups then participated in another study in which the electrical conductance of four auricular acupuncture points was measured, which involved acupressure to these four points. This additional treatment could have affected the main study results. After this study the women in the control group were given a placebo pill and put into the prone position for 30 minutes. The experimental group were hooked up to the TENS unit and also placed in the same position. The intensity of the TENS treatment was adjusted to the highest level tolerable by the participant.</P>
<P>
<LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK> (high-frequency TENS, low-frequency TENS, placebo TENS)<BR/>Women were treated with all three interventions during separate cycles. They were randomised to whichever treatment they received first. The electrodes used, their placement, and the procedure were kept the same for each treatment. For high-frequency TENS the stimulus intensity was below the pain threshold.</P>
<P>Electrodes were placed on the painful area (all participants complained of lower back pain) and TENS was applied for 20 minutes. If this resulted in pain relief then treatment was continued at the same stimulation point for a further 25 minutes. If there was no pain relief then electrodes were moved to either a trigger point or acupuncture point close to the area of pain. If no pain reduction was achieved at any of these points then electrodes were applied for 25 minutes within the painful area. For low-frequency TENS stimulus the intensity produced muscular contractions. For placebo TENS the apparatus was lacking electrical output but women were told it was ultra-high frequency TENS and that they may not experience any cutaneous sensation.</P>
<P>
<LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK> (high-frequency TENS, low-frequency TENS, placebo TENS)<BR/>All women were instructed separately by the same experimenter in the use of TENS and the expected stimulation sensation for each group. Women were then randomised to: 1) conventional TENS, 2) acupuncture-like TENS, or 3) placebo TENS. The instructions the women received differed on a group basis by the method of adjusting stimulation parameters, electrode placement, and description of electrical sensations.</P>
<P>All participants used the same type of portable TENS unit and the only non-fixed variable was intensity of stimulation. Women in the conventional TENS group were instructed to use an intensity that produced a comfortable, perceptible paraesthesia without muscle contraction. The acupuncture-like TENS group were to use an intensity that produced visible rhythmic muscle contractions. The placebo-TENS group was told to set it at maximum and that they may or may not experience a mild tingling sensation. The placebo group was also told that if a LED light came on their unit was non-functional; this was not possible however as dead batteries were used.</P>
<P>All participants were given instruction cards that illustrated electrode placement. Placement was the same for groups one and three. Those in group two placed the electrodes on acupuncture points and were instructed how to find the area of greatest tenderness. Treatment for all groups was 30 minutes in duration then discontinued until pain returned; a record of use was kept. Pain was rated immediately before and after TENS use.</P>
<P>
<LINK REF="STD-Milsom-1994" TYPE="STUDY">Milsom 1994</LINK> (high-frequency, high-intensity TENS, naproxen)<BR/>Women were randomly allocated to either high-intensity TENS or a single dose of naproxen (500 mg). Randomisation occurred after intrauterine pressure had been recorded for 30 minutes via a catheter. Treatment was performed at an outpatient clinic during the first 24 hours of the women's cycles. For the following cycle, participants received the therapy form not received in the first cycle.</P>
<P>For the TENS treatment electrodes were placed on the lower part of the abdomen and the back. It is unclear whether electrode placement was the same for all participants. The intensity of the electrical stimulation was gradually increased and women were informed that they might experience some pain. After 10 seconds, if the participant had not adapted to the intensity it was reduced to a more acceptable level. At 60 seconds of treatment the stimulator was switched off; if pain had not disappeared by this time then participants received a further 60 to 120 seconds of stimulation. Once analgesia had been achieved in the stimulated area some women felt pain in neighbouring regions. In these cases stimulation was repeated until pain relief was obtained. No information was given about how many women received reduced intensity stimulation or additional stimulation. All measurements lasted at least four hours for both treatment groups; pain relief was measured every 15 minutes with women in the supine position.</P>
<P>
<LINK REF="STD-Neighbors-1987" TYPE="STUDY">Neighbors 1987</LINK> (low-frequency TENS, placebo pill)<BR/>Treatment was scheduled when the participant called to report pain. Participants were randomly allocated to low-frequency TENS or a placebo pill. All participants were positioned prone on a treatment table for 30 minutes. The placebo group were told they were taking a "drug that has been used in the past for pain relief". The TENS group had eight electrodes attached to four acupuncture points bilaterally and the TENS unit was started. The intensity was slowly increased to a level as intense as was tolerable. After five minutes the intensity was increased, if tolerable. Total treatment time was 30 minutes. Pain assessment occurred prior to treatment and immediately after; participants were sent home with further measures to be completed at 30, 90, and 150 minutes following treatment.</P>
<P>
<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK> (acupuncture: manual stimulation, low-frequency electrical stimulation, high-frequency electrical stimulation, periosteal stimulation; TENS: low-frequency, high-frequency, and placebo TENS)<BR/>Acupuncture treatment was performed by one of two trained professionals, TENS treatment was administered by a trained physiotherapist. It is unclear how participants were placed in the TENS or acupuncture group. The acupuncture group were allocated to four different modes of treatment, one per cycle. Entry to the initial treatment was random and followed by the other treatments in a predetermined order, the fifth-cycle treatment was a mode of the participants's choice. </P>
<P>The TENS group were allocated to three different modes of treatment, one per cycle. Entry to the initial treatment was random and followed by the other treatments in a predetermined order, the fourth-cycle treatment was a mode of the participant's choice. For the placebo TENS group there was no electrical output to the electrodes and participants were told it was an ultra-high frequency mode where skin sensations might or might not be perceptible. All treatments (except periosteal stimulation) lasted 20 minutes; all outcome assessments were performed in the same manner. Two treatments were performed each cycle at approximately seven days and three days prior to the onset of menstruation.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-07-13 23:47:02 +1200" MODIFIED_BY="[Empty name]">
<P>
<BR/>One trial was excluded from the review (<LINK REF="STD-Janke-1984" TYPE="STUDY">Janke 1984</LINK>). The trial compared low-frequency TENS with a control that was a mixture of high-frequency TENS and placebo TENS. This combination did not clearly fit any of the intended comparisons so the trial was excluded. For more information see the table 'Characteristics of excluded studies'.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-14 12:51:05 +1200" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2009-07-13 23:48:24 +1200" MODIFIED_BY="[Empty name]">
<P>
<BR/>One included study was given an allocation score of A as correspondence with the author revealed that random allocation was performed via a centralised randomisation process (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>). Other included studies were given an allocation score of B due to unclear allocation concealment, except <LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK> which was given an allocation score of C for alternate allocation. One trial reported no information on randomisation or allocation (<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>). The remaining trials stated that allocation was random but failed to give adequate details regarding the method of allocation or concealment. This represents a source of potential bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-07-14 12:50:04 +1200" MODIFIED_BY="[Empty name]">
<P>
<BR/>In one trial the participants and the investigators were both blind to assignment status (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>). In two trials only the participants were blinded (<LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>; <LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>). Two trials were open due to the different types of interventions used (that is TENs versus placebo pill or naproxen) (<LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK>; <LINK REF="STD-Milsom-1994" TYPE="STUDY">Milsom 1994</LINK>). The remaining two trials gave no information regarding blinding of assignment status (<LINK REF="STD-Neighbors-1987" TYPE="STUDY">Neighbors 1987</LINK>; <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>); one of these trials was probably open as it compared TENS with a placebo pill, two quite different types of interventions (<LINK REF="STD-Neighbors-1987" TYPE="STUDY">Neighbors 1987</LINK>). The other trial involved two arms of treatment, acupuncture and TENS (<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>). While blinding may have been possible in the TENS arm, the four different types of acupuncture that were compared were too different for the women to have remained unaware of the differences in the interventions so double-blinding would have been impossible. Lack of blinding represents a potential source of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-07-14 12:51:05 +1200" MODIFIED_BY="[Empty name]">
<P>All but one of the studies (<LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK>) analysed all the patients. <LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK> did not analyse the final data from two patients but did use the last-observation-carried-forward method.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-05-05 12:39:44 +1200" MODIFIED_BY="Julie A Brown">
<P>All of the main outcomes were reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-06-16 12:44:48 +1200" MODIFIED_BY="Julie A Brown">
<P>No other potential sources of bias were identified.</P>
<P>
<BR/>
</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-10 14:34:02 +1200" MODIFIED_BY="jane clarke">
<P>Overall seven studies that involved transcutaneous electrical nerve stimulation for the treatment of primary dysmenorrhoea were identified and included. The studies involved a total of 164 participants.</P>
<SUBSECTION>
<HEADING LEVEL="5">1) High-frequency TENS versus placebo</HEADING>
<P>Refer to <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>
</P>
<P>There were four studies comparing the use of high-frequency TENS with placebo TENS for the treatment of dysmenorrhoea (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>; <LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>; <LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>; <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>). Overall results showed that high-frequency TENS was more effective for pain relief than placebo TENS. For pain relief reported as a dichotomous variable the OR was 7.2 (95% CI 3.1 to 16.5) in favour of high-frequency TENS (two trials). When pain relief was measured with a VAS the weighted mean difference (WMD) was 45.0 (95% CI 22.5 to 67.5) in favour of high-frequency TENS (one trial). One trial could not be included in the meta-analysis due to the form in which results were reported but was included as descriptive data; it found no difference between high-frequency TENS and placebo TENS for pain relief.</P>
<P>Only one of the trials reported any adverse effects associated with treatment (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>): 4/32 women using high-frequency TENS experienced muscle vibrations, tightness, and headaches after use and slight redness or burning of the skin (OR 8.2, 95% CI 1.1 to 60.9). There were no reported adverse effects from placebo TENS.</P>
<P>Two trials reported data on the use of analgesics additional to the TENS treatment (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a;</LINK> <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995)</LINK>. There was no significant difference in the number of women needing additional analgesics between high-frequency and placebo TENS (one trial; OR 0.3, 95% CI 0.1 to 1.1). There was also no significant difference in the number of analgesic tablets taken between the two groups (one trial; WMD 0.1, 95% CI -2.1 to 2.4).</P>
<P>One trial reported absence from work or school as the number of lost hours per menstrual cycle (<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>). There was no significant difference between high-frequency and placebo TENS for this outcome (WMD 0.04, 95% CI -0.4 to 0.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2) Low-frequency TENS versus placebo </HEADING>
<P>Refer to <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>
</P>
<P>There were three studies comparing the use of low-frequency TENS with placebo TENS (<LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>; <LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>; <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>) and two studies comparing low-frequency TENS with a placebo pill (<LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK>; <LINK REF="STD-Neighbors-1987" TYPE="STUDY">Neighbors 1987</LINK> ) for the treatment of dysmenorrhoea. Overall results suggested no significant difference between low-frequency TENS and placebo TENS or a placebo pill for pain relief. For pain relief reported as a dichotomous variable the OR was 1.48 (95% CI 0.43 to 5.08) when comparing low-frequency TENS and placebo TENS (one trial); and the OR was 2.9 (95% CI 0.35, 24.4) when comparing low-frequency TENS and placebo pill (one trial). When pain relief was measured using a VAS the WMD was 24.1 (95% CI -2.73 to 51.95; 1 trial). Two trials could not be included in the meta-analysis due to the form the results were reported in but they were included as descriptive data. One trial comparing low-frequency TENS and placebo TENS reported a significant difference between low-frequency TENS and placebo TENS in pain relief (P &lt; 0.05); the other trial showed that low-frequency TENS was more effective at reducing pain than a placebo pill (P &lt; 0.05).</P>
<P>Only one trial reported any information on adverse effects (<LINK REF="STD-Lewers-1989" TYPE="STUDY">Lewers 1989</LINK>) and found there were none in either the TENS group or the placebo pill group.</P>
<P>One trial reported on the number of tablets of additional analgesic used (<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>): the low-frequency TENS group used significantly less than the placebo TENS group (WMD -3.1, 95% CI -5.5 to -0.7). No significant difference was reported between the two groups for absence from work or school (<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>) (WMD -0.2, 95% CI -0.6 to 0.2).</P>
<P>
<B>3) High-frequency TENS versus low-frequency TENS</B>
<BR/>There were three studies that compared high-frequency TENS with low-frequency TENS for the treatment of dysmenorrhoea (<LINK REF="STD-Lundeberg-1985" TYPE="STUDY">Lundeberg 1985</LINK>; <LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>; <LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>). For pain relief reported as a dichotomous variable the OR was 3.9 (95% CI 1.1 to 13.0; 1 trial) in favour of high-frequency TENS (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). When pain relief was measured with a VAS the WMD was 20.9 (95% CI -4.4 to 46.1) showing no significant difference between the two types of TENS but a trend towards high-frequency TENS as achieving more pain relief (one trial) (<LINK REF="STD-Mannheimer-1985" TYPE="STUDY">Mannheimer 1985</LINK>); see <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>. One trial could not be included in the meta-analysis due to the form the results were reported in and was included as descriptive data, it found low-frequency TENS to be more likely to reduce pain than high-frequency TENS.</P>
<P>There was a significant difference in favour of low-frequency TENS for the number of analgesic tablets taken in addition to TENS treatment (WMD 3.2, 95% CI 0.5 to 5.9). There was no significant difference between the two groups for the outcome of absence from work or school (WMD 0.2, 95% CI -0.2 to 0.6) (<LINK REF="STD-Thomas-1995" TYPE="STUDY">Thomas 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4) TENS versus medical treatment</HEADING>
<P>There were two trials that compared a medical therapy with TENS (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a)</LINK>; <LINK REF="STD-Milsom-1994" TYPE="STUDY">Milsom 1994</LINK>). One trial compared ibuprofen (a non-steroidal anti-inflammatory drug) with high-frequency TENS (<LINK REF="STD-Dawood-1990a" TYPE="STUDY">Dawood 1990a</LINK>). For the outcome of pain relief reported as a dichotomous variable ibuprofen proved to be significantly better at reducing pain (OR 0.3, 95% CI 0.1 to 0.8). This trial reported no significant difference between the two treatments for additional use of analgesics (OR 0.4, 95% CI 0.1 to 1.4) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
<P>Another trial compared high-frequency, high-intensity TENS with naproxen (a non-steroidal anti-inflammatory drug) (<LINK REF="STD-Milsom-1994" TYPE="STUDY">Milsom 1994</LINK>). For the outcome of pain relief there was no significant difference in the pain scores for each group. This trial is reported as descriptive data as it could not be used in the meta-analysis.</P>
<P>There was a significant difference between high-frequency TENS and ibuprofen in the number of adverse effects experienced by participants (OR 26.7, 95% CI 5.5 to 130.9); 10/12 women in the TENS group experienced pain from the treatment while no adverse effects were reported by those taking ibuprofen. The women who reported pain from TENS stated that they were prepared to accept the short-term pain from the treatment in return for relief of dysmenorrhoea.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-07-14 13:20:49 +1200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-07-14 13:12:11 +1200" MODIFIED_BY="[Empty name]">
<P>This review aimed to assess the effectiveness of TENS and acupuncture for the treatment of primary dysmenorrhoea. Despite the growing popularity of complementary therapies there is a general lack of well-designed research to evaluate the effectiveness of these therapies to treat specific conditions.</P>
<P>Currently available data suggests that high-frequency TENS is effective in reducing primary dysmenorrhoea. Overall, high-frequency TENS was shown to be more effective for pain relief than placebo TENS. Low-frequency TENS was found to be no different in reducing pain than placebo TENS although there is a trend towards efficacy. There were conflicting results regarding whether high-frequency TENS is more effective than low-frequency TENS. The small number of participants in the majority of included trials is reflected by the wide confidence intervals and lack of precision in many of the comparisons, meaning that clear recommendations for practice cannot be made.<BR/>
</P>
<P>TENS may be an alternative treatment option for women with dysmenorrhoea who wish to stop using non-steroidal anti-inflammatory drugs (NSAIDs), oral contraceptives, or other analgesics because the existing medication is ineffective, has unacceptable adverse effects, or due to personal choice. An effective non-pharmacological method of treating dysmenorrhoea would be of great potential value in treating dysmenorrhoea; however, there are a number of problems with the trials included in this review and research into physical therapies in general.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-05-05 13:20:00 +1200" MODIFIED_BY="Julie A Brown">
<P>The evidence reported here represents small studies which may not be adequately powered to answer the clinical question. The participants and outcomes are representative and valid.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-07-14 13:13:09 +1200" MODIFIED_BY="[Empty name]">
<P>The data presented in this review were from seven RCTs involving 164 women with dysmenorrhoea. The main methodological problems are explored below in the potential biases but are also represented by the small number of women included in the studies and the lack of data which could be entered into a meta-analysis. Blinding of this type of intervention is methodologically difficult and rarely conducted.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-07-14 13:20:49 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="6">Use of a control or placebo group</HEADING>
<P>A difficult issue in all randomised controlled trials of physical and complementary therapies is the choice of an adequate control or placebo treatment. To control adequately for all the factors that may contribute to the treatment as a comparable placebo treatment, rather than a waiting list control or a no-treatment control, is preferable. Placebo TENS typically consists of TENS units and electrodes set up just like the real TENS but with no electrical output to the electrodes. This means the only potential difference in treatment is the lack of physical stimulation of the skin, making it a good control that can be easily blinded. Placebo TENS can also take the form of working electrodes attached to the wrong meridian points although this is not necessarily an effective control as there is a theoretical opportunity to create adverse effects or possibly a therapeutic effect by stimulating any meridian or acupuncture point. There is no guarantee that using mock TENS on a part of the meridian or other point will have no effect.</P>
<P>Another important aspect to the design of the control arm of these trials is to ensure that participants remain blinded to their group allocation. One way to achieve this is to recruit participants naive to the treatment being evaluated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Blinding</HEADING>
<P>Double blinding (both the participant and the treatment provider) in physical therapies is generally considered impossible as the treatment provider needs to physically deliver the treatment or placebo. Single blinding (of the participant) is also considered difficult, especially if the control is a different type of treatment for example TENS versus a placebo pill.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Standardisation of treatment</HEADING>
<P>Physical therapies are performed with variations by treatment providers. Treatment is often individually tailored to each participant's set of symptoms. Even if this is not the case the different therapists vary the duration of treatment, the exact placement of electrodes, the frequency of electrical stimulation, frequency of treatments, timing of treatments in the cycle, the number of treatments performed, and the individuality of treatment; for example stimulation intensity and pulse duration are often adjusted to participants' tolerance levels.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Traditional versus western medical approach</HEADING>
<P>TENS uses meridian points for the placement of electrodes. The western approach often advocates placement in the areas that are painful (for example the abdomen and the lower back). These different approaches to dysmenorrhoea can affect how treatments are performed, who receives treatment, and the end results for the outcomes measured. The impact of these factors on treatment outcome is not clear as these types of variations between practitioners of TENS can also be found in conventional medicine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other methodological issues</HEADING>
<P>With TENS some of the included trials used self-administered treatment whereas others were physician administered. For self-administered treatments the tendency is to place electrodes on the painful areas, while physician-administered treatments are more likely to be administered on meridian points.</P>
<P>Another aspect that could affect the evaluation of the treatments is the differences in the physiological effects of the two different types of TENS. With high-frequency TENS a small portable unit can be used, therefore users are able to carry on daily activities. However with low-frequency TENS the low rate triggers rhythmic muscle contractions which make it difficult for women to carry out daily activities.</P>
</SUBSECTION>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-14 13:24:17 +1200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-07-14 13:22:06 +1200" MODIFIED_BY="[Empty name]">
<P>The available data on high-frequency TENS suggest it is effective for the treatment of dysmenorrhoea. The clinical importance of the minor adverse effects that were reported in one study is unclear. TENS represents a suitable alternative for women who prefer not to use medication or wish to minimise their NSAID consumption. There are some data to suggest that women using TENS are less likely to require additional analgesia, an observation that supports clinical advice to consider TENS as an option, although the degree of relief obtainable from TENS alone is less than that from analgesic drugs.</P>
<P>The present review has not demonstrated the efficacy of low-frequency TENS. This may be because the single study was insufficiently powered. Clear recommendations for practice cannot be made.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-14 13:24:17 +1200" MODIFIED_BY="[Empty name]">
<P>It is likely that women experiencing dysmenorrhoea will continue to seek advice on and treatment with TENS, therefore further research is needed to establish the optimal manner in which TENS modalities should be used. The condition is very common and the lifestyle impact and economic burden justifies a search for effective and acceptable treatments. Inclusion of cost comparisons and outcomes in clinical trials will enable better assessment of the true value of treatment interventions. There is a need to improve the quality of future randomised controlled trials. The methods of trials need to be fully described so as to aid the reader as to the validity and relevance of reported studies. In particular, allocation blinding needs to be meticulous within the practical constraints discussed above.</P>
<P>Methodologically sound and adequately powered clinical trials are needed evaluating the role of low-frequency TENS for primary dysmenorrhoea. More information is needed on the potential adverse effects of high-frequency TENS and the acceptability of TENS treatments to women needs to be explored using both questionnaires and qualitative methods.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-07-14 13:25:19 +1200" MODIFIED_BY="[Empty name]">
<P>The authors acknowledge the helpful comments of those who refereed previous versions of this review, and the authors of included trials that supplied extra information and data. Special thanks are also due to Stephen Kennedy for his work as a co-author on the protocol; Xu Jin for his attempts to search for trials in China; Sarah Hetrick, Review Group Coordinator, for her help with all the inevitable problems; and to Sue Furness, Trials Search Coordinator, for her assistance with identifying trials; Marian Showell and Julie Brown for their assistance in the update of the review in 2009.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-14 13:25:45 +1200" MODIFIED_BY="[Empty name]">
<P>Michelle Proctor: took the lead in writing the original protocol and review, performed initial searches of databases for trials, involved in selecting trials for inclusion, performed independent data extraction and quality assessment of the included trials, was responsible for statistical analysis and interpretation of the data.<BR/>Caroline Smith: involved in selecting trials for inclusion, performed independent data extraction and quality assessment of the included trials, contributed to discussion and interpretation of results.<BR/>Cindy Farquhar: initiated and conceptualised the review, commented on drafts of the protocol and review, and participated in the update of the review.<BR/>Will Stones: commented on drafts of the protocol and review.</P>
<P>Julie Brown: took the lead in the update of the review and the formatting for Revman 5.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-05-05 13:14:26 +1200" MODIFIED_BY="Julie A Brown">
<P>The original review contained reference to acupuncture. The trial associated with acupuncture has now been removed from this review and the role of acupuncture in the treatment of dysmenorrhoea will be the subject of a new review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-05-05 13:15:03 +1200" MODIFIED_BY="Julie A Brown">
<P>Trials relating to acupuncture have now been excluded from this review and will the subject of a new review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-10 14:24:24 +1200" MODIFIED_BY="jane clarke">
<STUDIES MODIFIED="2009-08-10 14:24:24 +1200" MODIFIED_BY="jane clarke">
<INCLUDED_STUDIES MODIFIED="2009-07-14 01:04:00 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dawood-1990a" MODIFIED="2009-07-14 01:00:12 +1200" MODIFIED_BY="[Empty name]" NAME="Dawood 1990a" YEAR="1990">
<REFERENCE MODIFIED="2009-07-14 01:00:12 +1200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dawood YM, Ramos J. Transcutaneous electrical nerve stimulation (TENS) for the treatment of primary dysmenorrhea: a randomized crossover comparison with placebo TENS and ibuprofen. Obstetrics &amp;amp; Gynecology 1990;75(4):656-660.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:00:12 +1200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY, Ramos J</AU>
<TI>Transcutaneous electrical nerve stimulation (TENS) for the treatment of primary dysmenorrhea: a randomized crossover comparison with placebo TENS and ibuprofen</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>75</VL>
<NO>4</NO>
<PG>656-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewers-1989" NAME="Lewers 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewers D, Clelland JA, Jacksin JR, Varner RE, Bergman J</AU>
<TI>Transcutaneous electrical nerve stimulation in the relief of primary dysmenorrhoea</TI>
<SO>Physical Therapy</SO>
<YR>1989</YR>
<VL>69</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundeberg-1985" MODIFIED="2009-07-14 01:01:44 +1200" MODIFIED_BY="[Empty name]" NAME="Lundeberg 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-07-14 01:01:44 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundeberg T, Bondesson L, Lundstrom V</AU>
<TI>Relief of primary dysmenorrhea by transcutaneous electrical nerve stimulation</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1985</YR>
<VL>64</VL>
<NO>6</NO>
<PG>491-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mannheimer-1985" NAME="Mannheimer 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Mannheimer JS, Whalen EC. the efficacy of transcutaneous electrical nerve stimulation in dysmenorrhea. Clinical Journal of Pain 1985;1(2):75-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mannheimer JS, Whalen EC</AU>
<TI>The efficacy of transcutaneous electrical nerve stimulation in dysmenorrhea</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>2</NO>
<PG>75-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milsom-1994" MODIFIED="2009-07-14 01:03:28 +1200" MODIFIED_BY="[Empty name]" NAME="Milsom 1994" YEAR="">
<REFERENCE MODIFIED="2009-07-14 01:02:14 +1200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hedner N, Milsom I, Eliasson T, Mannheimer C. Tens bra vid smatsam mens. [TENS is effective in painful menstruation]. Lakartidningen 1996;93(13):1219-1222.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:02:14 +1200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedner N, Milsom I, Eliasson T, Mannheimer C</AU>
<TI>TENS is effective in painful menstruation</TI>
<TO>Tens bra vid smatsam mens</TO>
<SO>Lakartidningen</SO>
<YR>1996</YR>
<VL>93</VL>
<NO>13</NO>
<PG>1219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-14 01:03:28 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milsom I, Hedner N, Mannheimer C</AU>
<TI>A comparative study of the effect of high intensity transcutaneous nerve stimulation and oral naproxen on intrauterine pressure and menstrual pain in patients with primary dysmenorrhea</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>1</NO>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neighbors-1987" NAME="Neighbors 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neighbors LE, Clelland J, Jacksin JR, Bergman J, Orr J</AU>
<TI>Transcutaneous electrical nerve stimulation for pain relief in primary dysmenorrhea</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1987</YR>
<VL>3</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1995" MODIFIED="2009-07-14 01:04:00 +1200" MODIFIED_BY="[Empty name]" NAME="Thomas 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-14 01:04:00 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas M, Lundeberg T, Bjork G, Lundstrom-Lindstedt V</AU>
<TI>Pain and discomfort in primary dysmenorrhea is reduced by preemptive acupuncture or low frequency TENS</TI>
<SO>European Journal of Physical Medicine and Rehabilitation</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>3</NO>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-10 14:24:24 +1200" MODIFIED_BY="jane clarke">
<STUDY DATA_SOURCE="PUB" ID="STD-Janke-1984" MODIFIED="2009-08-10 14:24:24 +1200" MODIFIED_BY="jane clarke" NAME="Janke 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-08-10 14:24:24 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="BOOK">
<AU>Janke CL</AU>
<SO>Transcutaneous electrical nerve stimulation for pain relief in dysmenorrhoea [Master's thesis]</SO>
<YR>1984</YR>
<PB>University of Alabama in Birmingham</PB>
<CY>Birmingham, Alabama</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-10 14:24:00 +1200" MODIFIED_BY="jane clarke">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-05-04 11:57:25 +1200" MODIFIED_BY="Julie A Brown">
<STUDY DATA_SOURCE="PUB" ID="STD-Santiesteban-1985" MODIFIED="2009-05-04 11:57:25 +1200" MODIFIED_BY="Julie A Brown" NAME="Santiesteban 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-05-04 11:57:25 +1200" MODIFIED_BY="Julie A Brown" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santiesteban AJ, Burnham TL, George KL, Kita PJ, Mehring EA</AU>
<TI>Primary spasmodic dysmenorrhea: the use of TENS on acupuncture points</TI>
<SO>American Journal of Acupuncture</SO>
<YR>1985</YR>
<VL>13</VL>
<NO>1</NO>
<PG>35-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-07-14 01:10:56 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-07-14 01:10:56 +1200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Carroll-1996" NAME="Carroll 1996" TYPE="JOURNAL_ARTICLE">
<AU>Carroll D, Tramer M, McQuay H, Nye B, Moore A</AU>
<TI>Randomization is important in studies with pain outcomes: Systematic review of transcutaneous electrical nerve stimulation in acute postoperative pain</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1996</YR>
<VL>77</VL>
<PG>798-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroll-1997" NAME="Carroll 1997" TYPE="JOURNAL_ARTICLE">
<AU>Carroll D, Moore RA, Tramr MR, McQuay HJ</AU>
<TI>Transcutaneous electrical nerve stimulation does not relieve labour pain: updated systematic review</TI>
<SO>Contemporary Reviews in Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>Sept</VL>
<PG>195-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1984" MODIFIED="2009-07-14 01:05:15 +1200" MODIFIED_BY="[Empty name]" NAME="Dawood 1984" NOTES="&lt;p&gt;Dawood MY. Ibuprofen and dysmenorrhea. Am J Med. 1984;77(1A):87-94.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:05:15 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY</AU>
<TI>Ibuprofen and dysmenorrhea</TI>
<SO>The American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>1A</NO>
<PG>87-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1990b" MODIFIED="2009-07-14 01:05:57 +1200" MODIFIED_BY="[Empty name]" NAME="Dawood 1990b" NOTES="&lt;p&gt;Dawood MY. Dysmenorrhea. Clinical Obstetrics and Gynecology. 1990;33(1):168-178.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:05:57 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY</AU>
<TI>Dysmenorrhea</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>33</VL>
<NO>1</NO>
<PG>168-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gersh-1985" NAME="Gersh 1985" NOTES="&lt;p&gt;Gersh MR, Wolf SL. Applications of transcutaneous electrical nerve stimulation in the management of patients with pain. State-of-the-art update. Physical Therapy.1985; 65(3):314-36.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gersh MR, Wolf SL</AU>
<TI>Applications of transcutaneous electrical nerve stimulation in the management of patients with pain. State-of-the-art update</TI>
<SO>Physical Therapy</SO>
<YR>1985</YR>
<VL>65</VL>
<NO>3</NO>
<PG>314-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1997" MODIFIED="2009-07-14 01:07:46 +1200" MODIFIED_BY="[Empty name]" NAME="Kaplan 1997" NOTES="&lt;p&gt;Kaplan B, Rabinerson D, Pardo J, Krieser RU, Neri A. Transcutaneous electrical nerve stimulation (TENS) as a pain-relief device in obstetrics and gynecology. Clin Exp Obst &amp;amp; Gyn. 1997; 24(3):123-6.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:07:46 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan B, Rabinerson D, Pardo J, Krieser RU, Neri A</AU>
<TI>Transcutaneous electrical nerve stimulation (TENS) as a pain-relief device in obstetrics and gynecology</TI>
<SO>Clinical and Experimental Obstetrics &amp; Gynecology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>3</NO>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lichten-1987" MODIFIED="2009-07-14 01:08:47 +1200" MODIFIED_BY="[Empty name]" NAME="Lichten 1987" NOTES="&lt;p&gt;Lichten EM, Bombard J. Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation. J Repod Med. 1987;32:37-41.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:08:47 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lichten EM, Bombard J</AU>
<TI>Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation</TI>
<SO>The Journal of Reproductive Medicine</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1998" NAME="McQuay 1998" TYPE="BOOK_SECTION">
<AU>McQuay HJ, Moore RA</AU>
<TI>Transcutaneous electrical nerve stimulation (TENS) in chronic pain</TI>
<SO>An evidence-based resource for pain relief</SO>
<YR>1998</YR>
<PG>Chapter 25</PG>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osiri-2001" MODIFIED="2009-05-04 12:10:30 +1200" MODIFIED_BY="Julie A Brown" NAME="Osiri 2001" TYPE="COCHRANE_REVIEW">
<AU>Osiri M, Welch V, Brosseau L, Shea B, McGowan J, Tugwell P, Wells G</AU>
<TI>Transcutaneous electrical nerve stimulation for knee osteoarthritis (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2009-05-04 12:10:02 +1200" MODIFIED_BY="Julie A Brown">
<IDENTIFIER MODIFIED="2009-05-04 12:10:02 +1200" MODIFIED_BY="Julie A Brown" TYPE="DOI" VALUE="10.1002/14651858.CD002823."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Punnonen-1980" NAME="Punnonen 1980" TYPE="JOURNAL_ARTICLE">
<AU>Punnonen RH, Nikkanen VP</AU>
<TI>Endometriosis in young women</TI>
<SO>Infertility</SO>
<YR>1980</YR>
<VL>3</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheon-1984" MODIFIED="2009-07-14 01:09:58 +1200" MODIFIED_BY="[Empty name]" NAME="Sheon 1984" NOTES="&lt;p&gt;Sheon RP. Transcutaneous electrical nerve stimulation: From electric eels to electrodes. Postgraduate Medicine. 1984;75(5):71-74.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:09:58 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sheon RP</AU>
<TI>Transcutaneous electrical nerve stimulation: From electric eels to electrodes</TI>
<SO>Postgraduate Medicine</SO>
<YR>1984</YR>
<VL>75</VL>
<NO>5</NO>
<PG>71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1991" MODIFIED="2009-07-14 01:10:56 +1200" MODIFIED_BY="[Empty name]" NAME="Smith 1991" NOTES="&lt;p&gt;Smith RP, Heltzel J. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea: A preliminary report. J Reprod Med. 1991;36(4):260-264.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 01:10:56 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Smith RP, Heltzel J</AU>
<TI>Interrelation of analgesia and uterine activity in women with primary dysmenorrhea: A preliminary report</TI>
<SO>The Journal of Reproductive Medicine</SO>
<YR>1991</YR>
<VL>36</VL>
<NO>4</NO>
<PG>260-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-11-20 10:18:20 +1300" MODIFIED_BY="jane clarke">
<REFERENCE ID="REF-Proctor-2002" MODIFIED="2008-11-20 10:18:20 +1300" MODIFIED_BY="jane clarke" NAME="Proctor 2002" TYPE="COCHRANE_REVIEW">
<AU>Proctor ML, Smith CA, Farquhar CM, Stones RW</AU>
<TI>Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-20 10:18:20 +1300" MODIFIED_BY="jane clarke">
<IDENTIFIER MODIFIED="2008-11-20 10:18:20 +1300" MODIFIED_BY="jane clarke" TYPE="DOI" VALUE=" 10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-10 14:23:47 +1200" MODIFIED_BY="jane clarke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-10 14:23:47 +1200" MODIFIED_BY="jane clarke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-14 13:27:02 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dawood-1990a">
<CHAR_METHODS MODIFIED="2009-07-14 13:26:37 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised - method unstated in published trial. Communication from author stated it was a centralised randomisation process<BR/>Double blind - for type of TENS intervention<BR/>Crossover design<BR/>32 women randomised and analysed<BR/>Communication from author states that intention-to-treat analysis and a power calculation were used however no details were provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 13:26:44 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: severe primary dysmenorrhoea (diagnosed according to "predefined clinical criteria", regular cycles)<BR/>Exclusion: OCP use<BR/>Age: mean 28.5 (5.2) years<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:27:02 +1200" MODIFIED_BY="[Empty name]">
<P>1. Ibuprofen 400 mg every 6 hrs for 3 days<BR/>2. High-frequency TENS (conventional) - 100 pulses/sec, 100 &#956;sec pulse width, amplitude comfortable tingling<BR/>3. Placebo TENS<BR/>Location: abdomen (portable unit)<BR/>Duration: first 8hrs of cycle, then when needed for pain relief<BR/>5 cycles - TENS 2 cycles, placebo TENS 1 cycle, ibuprofen 1 cycle (sequence random)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain relief - scale 1-5<BR/>Menstrual symptom questionnaire<BR/>Use of pain medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-14 00:44:47 +1200" MODIFIED_BY="[Empty name]">
<P>Author supplied some unpublished methodological information<BR/>No information or baseline comparison on the groups pain characteristics</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-14 13:28:56 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewers-1989">
<CHAR_METHODS MODIFIED="2009-07-14 00:45:16 +1200" MODIFIED_BY="[Empty name]">
<P>Random - unstated in published trial. Correspondence with authors showed randomisation was done by flipping a coin for the first person and alternate assignment for other participants<BR/>No blinding<BR/>Parallel design<BR/>21 participants randomised and analysed (pain data estimated for two participants for last two recordings, 180min and next morning)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 13:28:13 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: primary dysmenorrhoea, pelvic exam in previous two years that showed no pathology<BR/>Age: 20-38, mean 25.9 years<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:28:31 +1200" MODIFIED_BY="[Empty name]">
<P>1. Low-frequency TENS - low rate 1 pulse/sec, highest intensity tolerable, pulse duration low, 40 msec<BR/>2. Placebo pill<BR/>Location: 4 points, bladder 21 and 29 (back), spleen 6 and stomach 36 (legs)<BR/>Duration: 30 min, 1 cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain scales - VAS and the pain rating index from McGill measured pre, post, 30, 60, 120, 180 min, next morning upon awakening</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-14 13:28:56 +1200" MODIFIED_BY="[Empty name]">
<P>No information on the baseline similarities of the randomised groups<BR/>Immediately after collection of baseline measurements all women received auricular acupressure, as part of another study prior to the intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-14 13:29:55 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundeberg-1985">
<CHAR_METHODS>
<P>Random - method unstated<BR/>Single blind, participant was blind but other unclear<BR/>Crossover design<BR/>21 women randomised and analysed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 00:46:33 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: primary dysmenorrhoea, gynaecological exam to rule out pathology<BR/>Age: average 22, 15-29 years<BR/>Location: Sweden</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:29:55 +1200" MODIFIED_BY="[Empty name]">
<P>1. High-frequency TENS - duration 0.2 msec, freq 100 Hz<BR/>2. Low-frequency TENS - duration 0.2 msec, freq 2 Hz<BR/>3. Placebo TENS<BR/>Location: source of pain, lower back or abdomen<BR/>Duration: 45 min treatment once every month<BR/>On fourth month patient given treatment of choice and asked to compare with 500mg naproxen, fifth month asked to compare with 120mg verapamil (calcium-channel blocker)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 00:47:12 +1200" MODIFIED_BY="[Empty name]">
<P>Pain intensity VAS 0-10<BR/>McGill pain questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No difference in baseline scores</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-14 13:30:56 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mannheimer-1985">
<CHAR_METHODS>
<P>Random - unstated<BR/>Parallel design<BR/>27 women randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 00:47:46 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: dysmenorrhoea, abdominal pain, women who were not previous users of TENS<BR/>Exclusion: OCP use, any precautions or contraindications to treatment, only lower back pain<BR/>Age: 19-27, mean 22.1 years<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:30:56 +1200" MODIFIED_BY="[Empty name]">
<P>1. Conventional high-freq TENS - 50-100 Hz, narrow pulse 40-75 &#956;sec, intensity produces no muscle contractions<BR/>2. Acupuncture-like low-frequency TENS - 1-4 Hz, pulse 100-250 &#956;sec, intensity to tolerance<BR/>3. Control - placebo TENS<BR/>Location: conventional and control used electrodes on abdomen, acupuncture-like TENS used points spleen 6 and 10 (legs)<BR/>Duration: 30 min - until pain returned<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain ratings - pre and post treatment<BR/>Duration of pain relief</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No information on the baseline similarities of the randomised groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-14 13:31:50 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Milsom-1994">
<CHAR_METHODS>
<P>Random - unstated<BR/>No blinding<BR/>Crossover design<BR/>12 women randomised and analysed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 00:49:12 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: severe primary dysmenorrhoea, abdomen and back pain<BR/>Exclusion: OCP, IUD, pelvic pathology on gynaecological exam<BR/>Age: mean 23.8 (0.8) years<BR/>Location: Sweden</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:31:50 +1200" MODIFIED_BY="[Empty name]">
<P>1. High frequency and intensity TENS - 70-100 Hz, 0.2 msec current/pulse duration, intensity 40-50 mA<BR/>2. Naproxen - single dose 500mg<BR/>Location: electrodes placed on lower abdomen and back<BR/>Duration: until pain free (2 cycles, one treatment per cycle)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score - 1-5 scale every 15 min for 240 min<BR/>Uterine activity<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No difference in baseline scores</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-14 13:32:45 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neighbors-1987">
<CHAR_METHODS MODIFIED="2009-07-14 00:50:00 +1200" MODIFIED_BY="[Empty name]">
<P>Random - unstated<BR/>No blinding<BR/>Parallel design, 20 women randomised and analysed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 00:50:21 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: dysmenorrhoea, pelvic exam in last two years that had shown no pelvic pathology<BR/>Age: 19-38 years<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:32:24 +1200" MODIFIED_BY="[Empty name]">
<P>1. Low-frequency TENS - pulse width 40 msec, rate 1 pulse/sec, intensity 0 mA then increased to tolerance<BR/>2. Placebo pill<BR/>Location: bladder 21 and 29 (back), spleen 6 and stomach 36 (legs)<BR/>Duration: 30min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 13:32:45 +1200" MODIFIED_BY="[Empty name]">
<P>Pain scales - VAS and abbreviated McGill<BR/>Measured pre, post, 30 min, 1 hr, 2 hr</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-14 00:51:38 +1200" MODIFIED_BY="[Empty name]">
<P>Check this is low frequency<BR/>No difference in baseline scores</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-14 13:34:09 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomas-1995">
<CHAR_METHODS>
<P>Not stated if random<BR/>Blinding unclear<BR/>Crossover design<BR/>31 women randomised, 29 analysed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 13:33:13 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: primary dysmenorrhoea, previous ineffective treatment with NSAIDs, contraindications to NSAIDs, gynaecological exam to rule out pathology, women with no previous use of TENS<BR/>Age: mean 30.2 (7.3) years<BR/>Location: Sweden</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:34:09 +1200" MODIFIED_BY="[Empty name]">
<P>7 treatments - participants split into two groups: TENS or acupuncture<BR/>Duration: 20 min treatment, 7 days and 3 days prior to onset of menstruation every month<BR/>Acupuncture treatments:<BR/>different mode each month for 4 months then preferred treatment for 5th month<BR/>Location: 5 points, bladder 32 (back, bilateral), abdomen CV4, spleen 9 and 6 (legs)<BR/>1. manual stimulation at insertion, every 5 min<BR/>2. low-frequency electrical stimulation at 2 Hz to evoke muscle contractions<BR/>3. high-frequency 100 Hz, intensity adjusted to comfort level<BR/>4. periosteal stimulation (for 30 sec) 3 or 4 times for each point<BR/>TENS treatments:<BR/>3 different modes for 3 months, patients preferred treatment for 4th month, pulse duration 0.2 msec<BR/>Location: Thoracic 10 to Lumbar 1<BR/>1. Low-frequency TENS, 2 Hz<BR/>2. High-frequency TENS, 100 Hz<BR/>3. Placebo TENS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain scale - VAS<BR/>Blood loss<BR/>Nausea<BR/>Hours of work lost<BR/>Analgesics taken (no mention of type or dose)<BR/>Subjective assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No information on the baseline similarities of the randomised groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>OCP: oral contraceptive pill</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-14 13:36:05 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-14 13:36:05 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janke-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-14 13:36:05 +1200" MODIFIED_BY="[Empty name]">
<P>The trial compared low-frequency TENS with a control that was a mixture of high-frequency TENS and placebo TENS. This combination did not clearly fit any of the intended comparisons of the review so the trial was excluded.<BR/>Methods: low-frequency TENS, high-frequency TENS, and placebo TENS<BR/>Participants were divided into two treatment groups. The experimental group received low-frequency TENS to four acupuncture points bilaterally. Intensity of stimulation was adjusted to a level as intense as tolerable for 30 min (varied from 35-70 amps). If the participant reached the maximum intensity and could take a stronger stimulation the pulse width was adjusted to a tolerable level for 30 min (varied from 40-100 msec). The control group received high-frequency TENS to four non-acupuncture points close to the acupuncture points used in the experimental group, the intensity was adjusted to a just noticeable level. Electrodes were also placed on the same back points as those used for the experimental group but current was not delivered. Outcome assessment was the same for both treatment groups.</P>
<P>Not stated if random<BR/>No information on blinding<BR/>Parallel design<BR/>20 participants, 10 in each group<BR/>No drop outs</P>
<P>Participants:<BR/>Inclusion: self-reported dysmenorrhoea, aged between 18-40 years<BR/>Exclusion: known pelvic pathology, other medical problems, use of NSAIDs or other pain medication 4 hr prior to treatment<BR/>Age: mean 25.7, range 19-40 years<BR/>Location: Alabama, USA<BR/>Source: volunteers from university area</P>
<P>Interventions:<BR/>1. Experimental group acupuncture-like (low rate) TENS over four acupuncture points bilaterally, intensity 0 mA initially (adjusted to a level as intense as tolerable between 35-70 mA), pulse width 40 msec initially (adjusted to within 40-100 msec as tolerable, rate 1pulse/sec<BR/>2. Control group of conventional TENs to 4 non-acupuncture points, rate 40 pulses/sec width 100msec. Electrodes were also placed on 4 acupuncture points but no current delivered.<BR/>Location: Acupuncture points Spleen 6, Stomach 36, Bladder 21, Bladder 29 were used for the experimental group. For the control electrodes were placed on B21 and B29 bilaterally but not stimulated. Two non-acupuncture points on the leg near ST36 and SP6 were stimulated<BR/>Duration: 30 min treatment while subject was experiencing dysmenorrhoea, for one cycle</P>
<P>Outcomes:<BR/>Pain scores - VAS (0-10 cm) and McGill Pain Rating Index (scores 1-78) taken at baseline, 30, 60, 90, 150, 210 min after start of treatment.<BR/>Raw data reported for each participant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-07-14 13:36:38 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-07-14 13:36:38 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santiesteban-1985">
<CHAR_METHODS MODIFIED="2009-05-04 11:57:25 +1200" MODIFIED_BY="Julie A Brown">
<P>Participants blinded<BR/>Parallel design<BR/>8 women randomised and analysed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-14 00:42:24 +1200" MODIFIED_BY="[Empty name]">
<P>Inclusion: dysmenorrhoea<BR/>Exclusion: any medication<BR/>Age: average 22 years<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 13:36:28 +1200" MODIFIED_BY="[Empty name]">
<P>1. Low-frequency TENS - 5 Hz pulse rate, 250 &#956;sec, pulse duration/intensity to patients tolerance<BR/>2. Sham (mock) TENS - no intensity administered<BR/>Duration: 30 min<BR/>Location: Spleen 6, Gallbladder 34 (on legs)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 13:36:38 +1200" MODIFIED_BY="[Empty name]">
<P>Pain scale 1-5 measured pre, post, 4 hrs, 24 hrs, 30 days<BR/>Abdominal pain<BR/>Back pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-14 00:43:13 +1200" MODIFIED_BY="[Empty name]">
<P>No difference between the experimental and control group for pretreatment abdominal pain, however there was some difference for pretreatment back pain with the control group having a higher average pain rating<BR/>
</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-10 14:23:47 +1200" MODIFIED_BY="jane clarke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-14 13:34:27 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:27:23 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dawood-1990a">
<DESCRIPTION>
<P>"..enrolled in a randomized crossover study" - method unstated in published trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:29:09 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lewers-1989">
<DESCRIPTION>
<P>"Subjects were assigned randomly". No further details in paper. Correspondence with authors showed randomisation was done by flipping a coin for the first person and alternate assignment for other participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:30:21 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lundeberg-1985">
<DESCRIPTION>
<P>"Randomly assigned to one of three groups", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:31:24 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mannheimer-1985">
<DESCRIPTION>
<P>"randomly assigned" no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:32:10 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milsom-1994">
<DESCRIPTION>
<P>"randomised", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:32:59 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neighbors-1987">
<DESCRIPTION>
<P>"randomly assigned" no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 13:34:27 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thomas-1995">
<DESCRIPTION>
<P>"randomised although serial order was maintained".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-10 14:23:47 +1200" MODIFIED_BY="jane clarke" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 11:16:10 +1200" MODIFIED_BY="Julie A Brown" RESULT="YES" STUDY_ID="STD-Dawood-1990a">
<DESCRIPTION>
<P>No details provided. Communication from author stated it was a centralised randomisation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:45:52 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lewers-1989">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 14:23:19 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Lundeberg-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 14:23:28 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Mannheimer-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 14:23:37 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Milsom-1994">
<DESCRIPTION>
<P>Unclear, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 14:23:39 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Neighbors-1987">
<DESCRIPTION>
<P>Unclear, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 14:23:47 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Thomas-1995">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-07-14 13:27:43 +1200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 13:27:43 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dawood-1990a">
<DESCRIPTION>
<P>Double blind - for type of TENS intervention. "subjects and investigators were blinded as to the type of transcutaneous electrical nerve stimulator..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 00:45:55 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lewers-1989">
<DESCRIPTION>
<P>No blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 00:47:24 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lundeberg-1985">
<DESCRIPTION>
<P>Single blind, participant was blind but other unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 00:48:43 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mannheimer-1985">
<DESCRIPTION>
<P>No details of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 00:49:46 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Milsom-1994">
<DESCRIPTION>
<P>Open-label study, no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 00:51:54 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neighbors-1987">
<DESCRIPTION>
<P>No evidence of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-14 00:53:56 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thomas-1995">
<DESCRIPTION>
<P>Participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-14 00:53:58 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:45:08 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dawood-1990a">
<DESCRIPTION>
<P>All patients followed up, no apparent drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:46:12 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lewers-1989">
<DESCRIPTION>
<P>Two participants in the experimental group did not complete posttreatment measures as they were asleep and needing to take additional medication, therefore used last value carried forward.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:47:27 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundeberg-1985">
<DESCRIPTION>
<P>All 21 patients were analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:48:46 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mannheimer-1985">
<DESCRIPTION>
<P>All patients were analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:49:49 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Milsom-1994">
<DESCRIPTION>
<P>All patients analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:51:56 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neighbors-1987">
<DESCRIPTION>
<P>All patients analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-14 00:53:58 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thomas-1995">
<DESCRIPTION>
<P>All patients analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-07-14 00:54:00 +1200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:45:10 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dawood-1990a">
<DESCRIPTION>
<P>All relevant outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:46:18 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lewers-1989">
<DESCRIPTION>
<P>Main outcome measures were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:47:33 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundeberg-1985">
<DESCRIPTION>
<P>All major and relevant outcomes reported on.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:48:48 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mannheimer-1985">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:49:51 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Milsom-1994">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:52:00 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neighbors-1987">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-14 00:54:00 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thomas-1995">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-07-14 12:22:04 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-07-14 00:38:41 +1200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-14 00:38:41 +1200" MODIFIED_BY="[Empty name]">TENS modalities - high frequency</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Hz; freq; pulse rate</P>
</TH>
<TH>
<P>Pulse width</P>
</TH>
<TH>
<P>Intensity</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD>
<P>Dawood 1990</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>100 microsec</P>
</TD>
<TD>
<P>comfortable tingling</P>
</TD>
<TD>
<P>Tenzcare portable unit used</P>
</TD>
</TR>
<TR>
<TD>
<P>Lundeberg 1985</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>200 microsec</P>
</TD>
<TD>
<P>low intensity - below pain threshold</P>
</TD>
<TD>
<P>square wave pulses</P>
</TD>
</TR>
<TR>
<TD>
<P>Mannheimer</P>
</TD>
<TD>
<P>50-100</P>
</TD>
<TD>
<P>40-75 microsec</P>
</TD>
<TD>
<P>comfortable</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Milsom</P>
</TD>
<TD>
<P>70-100</P>
</TD>
<TD>
<P>200 microsec</P>
</TD>
<TD>
<P>high - 40-50 mA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Thomas 1995</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>200 microsec</P>
</TD>
<TD>
<P>no info given</P>
</TD>
<TD>
<P>monopolar pulses</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-07-14 12:22:04 +1200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-14 00:39:00 +1200" MODIFIED_BY="[Empty name]">TENS modalities - low frequency</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Hz; freq; pulse rate</P>
</TH>
<TH>
<P>Pulse width</P>
</TH>
<TH>
<P>Intensity</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD>
<P>Lewers 1989</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>40 &#956;sec</P>
</TD>
<TD>
<P>highest tolerable</P>
</TD>
<TD>
<P>Note this trial used msec - also called hyperstimulation</P>
</TD>
</TR>
<TR>
<TD>
<P>Lundeberg 1985</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>200 &#956;sec</P>
</TD>
<TD>
<P>high, muscle contractions produces</P>
</TD>
<TD>
<P>pulse trains of 80 msec, 2/sec</P>
</TD>
</TR>
<TR>
<TD>
<P>Mannheimer 1985</P>
</TD>
<TD>
<P>1-4</P>
</TD>
<TD>
<P>100-250 &#956;sec</P>
</TD>
<TD>
<P>to tolerance level, with visible rhythmic muscle contractions</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neighbors 1987</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>40 &#956;sec</P>
</TD>
<TD>
<P>increased to tolerance</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Santiesteban 1985</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>250 &#956;sec</P>
</TD>
<TD>
<P>to tolerance level with minimum of palpable contractions</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Thomas 1995</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>200 &#956;sec</P>
</TD>
<TD>
<P>no information</P>
</TD>
<TD>
<P>Trains of monopolar square wave pulses with a duration of 0.2 msec</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-14 01:12:46 +1200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-14 01:11:31 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>High-frequency TENS versus placebo</NAME>
<DICH_OUTCOME CHI2="0.4057227523668421" CI_END="16.452689122535006" CI_START="3.130662032284476" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.176894116879539" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.216236891686061" LOG_CI_START="0.49563618628946604" LOG_EFFECT_SIZE="0.8559365389877636" METHOD="PETO" NO="1" P_CHI2="0.5241485041209322" P_Q="1.0" P_Z="3.2221066242087105E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="53" WEIGHT="99.99999999999999" Z="4.656128635190779">
<NAME>Pain relief - overall experience</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HF TENS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4057227523668421" CI_END="16.452689122535006" CI_START="3.130662032284476" DF="1.0" EFFECT_SIZE="7.176894116879539" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="8" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.216236891686061" LOG_CI_START="0.49563618628946604" LOG_EFFECT_SIZE="0.8559365389877636" NO="1" P_CHI2="0.5241485041209322" P_Z="3.2221066242087105E-6" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="99.99999999999999" Z="4.656128635190779">
<NAME>Placebo TENS</NAME>
<DICH_DATA CI_END="29.259632212097507" CI_START="2.9474312587602234" EFFECT_SIZE="9.286590041654888" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.4662688628261875" LOG_CI_START="0.4694436850854492" LOG_EFFECT_SIZE="0.9678562739558184" ORDER="36436" O_E="6.5" SE="0.5855400437691199" STUDY_ID="STD-Dawood-1990a" TOTAL_1="32" TOTAL_2="32" VAR="2.9166666666666665" WEIGHT="52.25782957028404"/>
<DICH_DATA CI_END="17.983825489583072" CI_START="1.6292203714839937" EFFECT_SIZE="5.412911863760747" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="1.2548820796274667" LOG_CI_START="0.21197983178946608" LOG_EFFECT_SIZE="0.7334309557084664" ORDER="36437" O_E="4.5" SE="0.6126059428294272" STUDY_ID="STD-Lundeberg-1985" TOTAL_1="21" TOTAL_2="21" VAR="2.664634146341464" WEIGHT="47.74217042971595"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="67.47237816110038" CI_START="22.527621838899613" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="45.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="8.682124877766634E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="3.924746133765831">
<NAME>Pain relief - 100pt VAS</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HF TENS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="67.47237816110038" CI_START="22.527621838899613" DF="0.0" EFFECT_SIZE="45.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="8.682124877766634E-5" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="3.924746133765831">
<NAME>Placebo TENS</NAME>
<CONT_DATA CI_END="67.47237816110038" CI_START="22.527621838899613" EFFECT_SIZE="45.0" ESTIMABLE="YES" MEAN_1="72.22" MEAN_2="27.22" ORDER="36438" SD_1="22.05" SD_2="26.4" SE="11.465709746893125" STUDY_ID="STD-Mannheimer-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pain relief - descriptive data</NAME>
<TR>
<TH>
<P>Pain scale used</P>
</TH>
<TH>
<P>HF TENS</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Conclusion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.03.01" NO="1" STUDIES="1">
<NAME>Placebo TENS</NAME>
<OTHER_DATA ORDER="150" STUDY_ID="STD-Thomas-1995">
<TR>
<TD>
<P>Total Pain measure on 100mm VAS 3 x day for 3 days<BR/>Max score = 900<BR/>Pretreatment scores<BR/>mean: 375<BR/>std dev: 157</P>
</TD>
<TD>
<P>mean: 353<BR/>std dev: 128<BR/>n=12</P>
</TD>
<TD>
<P>mean: 387<BR/>std dev: 167<BR/>n=12</P>
</TD>
<TD>
<P>No difference between High frequency TENS and Placebo TENS in reducing pain (using ANOVA, p&gt;0.05)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="60.84717819718891" CI_START="1.0959642339503928" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.16616991256765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.7842404425199752" LOG_CI_START="0.03979638147368287" LOG_EFFECT_SIZE="0.9120184119968289" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.04042397933824075" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.04939015319192">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.84717819718891" CI_START="1.0959642339503928" DF="0.0" EFFECT_SIZE="8.16616991256765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.7842404425199752" LOG_CI_START="0.03979638147368287" LOG_EFFECT_SIZE="0.9120184119968289" NO="1" P_CHI2="1.0" P_Z="0.04042397933824075" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.04939015319192">
<NAME>Placebo TENS</NAME>
<DICH_DATA CI_END="60.84717819718891" CI_START="1.0959642339503923" EFFECT_SIZE="8.16616991256765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7842404425199752" LOG_CI_START="0.03979638147368269" LOG_EFFECT_SIZE="0.9120184119968289" ORDER="36440" O_E="2.0" SE="1.02469507659596" STUDY_ID="STD-Dawood-1990a" TOTAL_1="32" TOTAL_2="32" VAR="0.9523809523809523" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1382899922268965" CI_START="0.08677534800322888" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.056252917577503364" LOG_CI_START="-1.0616036359616046" LOG_EFFECT_SIZE="-0.5026753591920505" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.07795027761606659" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.7627048780327907">
<NAME>Use of additional analgesics (n of women)</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1382899922268965" CI_START="0.08677534800322888" DF="0.0" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.056252917577503364" LOG_CI_START="-1.0616036359616046" LOG_EFFECT_SIZE="-0.5026753591920505" NO="1" P_CHI2="1.0" P_Z="0.07795027761606659" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.7627048780327907">
<NAME>Placebo TENS</NAME>
<DICH_DATA CI_END="1.1382899922268965" CI_START="0.08677534800322888" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.056252917577503364" LOG_CI_START="-1.0616036359616046" LOG_EFFECT_SIZE="-0.5026753591920505" ORDER="36441" O_E="0.0" SE="0.6566344730280548" STUDY_ID="STD-Dawood-1990a" TOTAL_1="32" TOTAL_2="32" VAR="0.43116883116883115" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.37559790358357" CI_START="-2.095597903583571" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.9023138128577085" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.1227389582875182">
<NAME>Use of additional analgesics (n of tablets taken)</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.37559790358357" CI_START="-2.095597903583571" DF="0.0" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.9023138128577085" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.1227389582875182">
<NAME>Placebo TENS</NAME>
<CONT_DATA CI_END="2.37559790358357" CI_START="-2.095597903583571" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" MEAN_1="6.92" MEAN_2="6.78" ORDER="36442" SD_1="3.22" SD_2="2.29" SE="1.1406321346808825" STUDY_ID="STD-Thomas-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.44807749249020146" CI_START="-0.3680774924902014" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8476506822886731" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.19211684257122982">
<NAME>Absence from work/school (lost hours)</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.44807749249020146" CI_START="-0.3680774924902014" DF="0.0" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.8476506822886731" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.19211684257122982">
<NAME>Placebo TENS</NAME>
<CONT_DATA CI_END="0.44807749249020146" CI_START="-0.3680774924902014" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.46" MEAN_2="1.42" ORDER="36443" SD_1="0.51" SD_2="0.51" SE="0.20820662813657015" STUDY_ID="STD-Thomas-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-14 01:11:51 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Low-frequency TENS versus placebo</NAME>
<DICH_OUTCOME CHI2="0.2875409556983641" CI_END="5.094235150629817" CI_START="0.6049662789598064" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.755517155490874" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.7070789881862665" LOG_CI_START="-0.21826883240509723" LOG_EFFECT_SIZE="0.2444050778905846" METHOD="PETO" MODIFIED="2009-05-04 11:57:26 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="0.5918007417213134" P_Q="0.5918007417213134" P_Z="0.3005098232176079" Q="0.2875409556983641" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.0353407435446729">
<NAME>Pain relief - overall experience</NAME>
<GROUP_LABEL_1>LF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LF TENS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.077652327963583" CI_START="0.43327290837092747" DF="0.0" EFFECT_SIZE="1.4832427959822332" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.7056629609693498" LOG_CI_START="-0.36323846562255513" LOG_EFFECT_SIZE="0.17121224767339738" MODIFIED="2009-05-04 11:57:26 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="1.0" P_Z="0.5300838747034358" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="74.94362560868002" Z="0.627877989127481">
<NAME>Placebo TENS</NAME>
<DICH_DATA CI_END="5.077652327963583" CI_START="0.43327290837092747" EFFECT_SIZE="1.4832427959822332" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.7056629609693498" LOG_CI_START="-0.36323846562255513" LOG_EFFECT_SIZE="0.17121224767339738" ORDER="36444" O_E="1.0" SE="0.627877989127481" STUDY_ID="STD-Lundeberg-1985" TOTAL_1="21" TOTAL_2="21" VAR="2.5365853658536586" WEIGHT="74.94362560868002"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.41356067258036" CI_START="0.34595419273909755" DF="0.0" EFFECT_SIZE="2.9061957391699407" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.3876311250820665" LOG_CI_START="-0.46098140166282825" LOG_EFFECT_SIZE="0.4633248617096191" NO="2" P_CHI2="1.0" P_Z="0.32587003706437134" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="25.056374391319977" Z="0.9824666109905368">
<NAME>Placebo Pill</NAME>
<DICH_DATA CI_END="24.41356067258036" CI_START="0.34595419273909755" EFFECT_SIZE="2.9061957391699407" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="1.3876311250820665" LOG_CI_START="-0.46098140166282825" LOG_EFFECT_SIZE="0.4633248617096191" ORDER="36446" O_E="0.9047619047619051" SE="1.0858841489895403" STUDY_ID="STD-Lewers-1989" TOTAL_1="10" TOTAL_2="11" VAR="0.8480725623582765" WEIGHT="25.056374391319977"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.732327582253364E-32" CI_END="50.94648791942822" CI_START="-2.726487919428216" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="24.110000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.0782656750316492" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="1.7608388925232927">
<NAME>Pain relief - 100pt VAS</NAME>
<GROUP_LABEL_1>LF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LF TENS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.732327582253364E-32" CI_END="50.94648791942822" CI_START="-2.726487919428216" DF="0.0" EFFECT_SIZE="24.110000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.0" P_Z="0.0782656750316492" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="1.7608388925232927">
<NAME>Placebo TENS</NAME>
<CONT_DATA CI_END="50.94648791942822" CI_START="-2.7264879194282194" EFFECT_SIZE="24.11" ESTIMABLE="YES" MEAN_1="51.33" MEAN_2="27.22" ORDER="36447" SD_1="31.47" SD_2="26.4" SE="13.692337273088185" STUDY_ID="STD-Mannheimer-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.03" MODIFIED="2009-05-04 12:11:25 +1200" MODIFIED_BY="Julie A Brown" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Pain relief - descriptive data</NAME>
<TR>
<TH>
<P>Pain scale used</P>
</TH>
<TH>
<P>LF TENS</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Conclusion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.03.01" NO="1" STUDIES="1">
<NAME>Placebo TENS</NAME>
<OTHER_DATA ORDER="158" STUDY_ID="STD-Thomas-1995">
<TR>
<TD>
<P>Total Pain measure on 100mm VAS 3 x day for 3 days<BR/>Max score = 900<BR/>Pretreatment scores<BR/>mean: 375<BR/>std dev: 157</P>
</TD>
<TD>
<P>mean: 245<BR/>std dev: 187<BR/>n=12</P>
</TD>
<TD>
<P>mean: 387<BR/>std dev: 167<BR/>n=12</P>
</TD>
<TD>
<P>Low Frequency TENS is more effective at reducing pain than Placebo TENS<BR/>(using ANOVA, p&lt;0.05)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.03.02" NO="2" STUDIES="1">
<NAME>Placebo Pill</NAME>
<OTHER_DATA ORDER="159" STUDY_ID="STD-Neighbors-1987">
<TR>
<TD>
<P>Mean pain scores on 10cm VAS</P>
</TD>
<TD>
<P>mean: 0.54<BR/>std dev: 0.79<BR/>n: 10<BR/>range: 0.00-2.00</P>
</TD>
<TD>
<P>mean: 3.30<BR/>std dev: 2.451<BR/>n: 10<BR/>range: 0.2-7.5</P>
</TD>
<TD>
<P>Low frequency TENS is more effective at reducing pain than Placebo pill (using ANOVA, p&lt;0.05)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2009-05-04 12:11:25 +1200" MODIFIED_BY="Julie A Brown" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Placebo Pill</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36450" O_E="0.0" SE="0.0" STUDY_ID="STD-Lewers-1989" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.3260692320458999E-31" CI_END="-0.6797946568443165" CI_START="-5.460205343155685" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0700000000000007" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2009-05-04 12:11:25 +1200" MODIFIED_BY="Julie A Brown" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.011822641978264197" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.00000000000001" Z="2.5173943526516704">
<NAME>Use of additional analgesics (n of tablets taken)</NAME>
<GROUP_LABEL_1>LF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3260692320458999E-31" CI_END="-0.6797946568443165" CI_START="-5.460205343155685" DF="0.0" EFFECT_SIZE="-3.0700000000000007" ESTIMABLE="YES" I2="100.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.0" P_Z="0.011822641978264197" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001" Z="2.5173943526516704">
<NAME>Placebo TENS</NAME>
<CONT_DATA CI_END="-0.6797946568443161" CI_START="-5.4602053431556845" EFFECT_SIZE="-3.0700000000000003" ESTIMABLE="YES" MEAN_1="3.71" MEAN_2="6.78" ORDER="36451" SD_1="3.55" SD_2="2.29" SE="1.2195149308912403" STUDY_ID="STD-Thomas-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.18743091809505202" CI_START="-0.5674309180950519" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2009-05-04 12:11:25 +1200" MODIFIED_BY="Julie A Brown" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.32381303887226165" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.986652495090047">
<NAME>Absence from work/school (lost hours)</NAME>
<GROUP_LABEL_1>LF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.18743091809505202" CI_START="-0.5674309180950519" DF="0.0" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" NO="1" P_CHI2="1.0" P_Z="0.32381303887226165" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.986652495090047">
<NAME>Placebo TENS</NAME>
<CONT_DATA CI_END="0.18743091809505202" CI_START="-0.5674309180950519" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" MEAN_1="1.23" MEAN_2="1.42" ORDER="36452" SD_1="0.43" SD_2="0.51" SE="0.19257033347152236" STUDY_ID="STD-Thomas-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-07-14 01:12:23 +1200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>High-frequency TENS versus low-frequency TENS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.041110085859545" CI_START="1.1423297169458464" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.859695272044097" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="1.1153145610004882" LOG_CI_START="0.057791474822883736" LOG_EFFECT_SIZE="0.586553017911686" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02969161716416752" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.00000000000001" Z="2.174180034755496">
<NAME>Pain relief - overall experience</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>LF TENS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HF TENS</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.041110085859545" CI_START="1.1423297169458464" EFFECT_SIZE="3.859695272044097" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="1.1153145610004882" LOG_CI_START="0.057791474822883736" LOG_EFFECT_SIZE="0.586553017911686" ORDER="36459" O_E="3.5" SE="0.6211942956444276" STUDY_ID="STD-Lundeberg-1985" TOTAL_1="21" TOTAL_2="21" VAR="2.591463414634146" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="46.13924316247309" CI_START="-4.359243162473096" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="20.89" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.10489347833135791" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="1.6215792043182735">
<NAME>Pain relief - 100pt VAS</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>LF TENS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HF TENS</GRAPH_LABEL_2>
<CONT_DATA CI_END="46.13924316247309" CI_START="-4.359243162473096" EFFECT_SIZE="20.89" ESTIMABLE="YES" MEAN_1="72.22" MEAN_2="51.33" ORDER="36460" SD_1="22.05" SD_2="31.74" SE="12.88250363865658" STUDY_ID="STD-Mannheimer-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Pain relief - descriptive data</NAME>
<TR>
<TH>
<P>Pain scale used</P>
</TH>
<TH>
<P>HF TENS</P>
</TH>
<TH>
<P>LF TENS</P>
</TH>
<TH>
<P>Conclusion</P>
</TH>
</TR>
<OTHER_DATA ORDER="165" STUDY_ID="STD-Thomas-1995">
<TR>
<TD>
<P>Total Pain on 100mm VAS scale - measured 3 x day for 3 days - Max score 900<BR/>Pretreatment score<BR/>mean: 375<BR/>std dev: 157</P>
</TD>
<TD>
<P>mean: 553<BR/>std dev: 128<BR/>n: 12</P>
</TD>
<TD>
<P>mean: 245<BR/>std dev: 187<BR/>n: 12</P>
</TD>
<TD>
<P>Low frequency TENS more likely to reduce pain than High frequency TENS<BR/>(using ANOVA p&lt;0.05)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.921730173774097" CI_START="0.4982698262259033" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.21" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2009-05-04 12:11:34 +1200" MODIFIED_BY="Julie A Brown" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.020335484016934975" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="2.3200997102220144">
<NAME>Use of additional analgesics (n of tablets taken)</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>LF TENS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LF TENS</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.921730173774097" CI_START="0.4982698262259033" EFFECT_SIZE="3.21" ESTIMABLE="YES" MEAN_1="6.92" MEAN_2="3.71" ORDER="36462" SD_1="3.22" SD_2="3.55" SE="1.3835612262081742" STUDY_ID="STD-Thomas-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6074309180950519" CI_START="-0.147430918095052" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-05-04 12:11:34 +1200" MODIFIED_BY="Julie A Brown" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.23233375349680208" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1943688098458467">
<NAME>Absence from work/school (lost hours)</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>LF TENS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HF TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LF TENS</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6074309180950519" CI_START="-0.147430918095052" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" MEAN_1="1.46" MEAN_2="1.23" ORDER="36463" SD_1="0.51" SD_2="0.43" SE="0.19257033347152236" STUDY_ID="STD-Thomas-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-07-14 01:12:46 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>TENS versus medical treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7516740446640457" CI_START="0.10381396422369281" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2793461336418167" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.12397044570148295" LOG_CI_START="-0.9837442247400097" LOG_EFFECT_SIZE="-0.5538573352207463" METHOD="PETO" MODIFIED="2009-05-04 12:11:48 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.011564007295314668" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.5251768687803797">
<NAME>Pain relief - overall experience</NAME>
<GROUP_LABEL_1>TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Medical treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Medical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TENS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7516740446640457" CI_START="0.10381396422369281" DF="0.0" EFFECT_SIZE="0.2793461336418167" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.12397044570148295" LOG_CI_START="-0.9837442247400097" LOG_EFFECT_SIZE="-0.5538573352207463" MODIFIED="2009-05-04 12:11:48 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="1.0" P_Z="0.011564007295314668" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.5251768687803797">
<NAME>Ibuprofen</NAME>
<DICH_DATA CI_END="0.7516740446640457" CI_START="0.10381396422369281" EFFECT_SIZE="0.2793461336418167" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="-0.12397044570148295" LOG_CI_START="-0.9837442247400097" LOG_EFFECT_SIZE="-0.5538573352207463" ORDER="36464" O_E="-5.0" SE="0.5050353737560759" STUDY_ID="STD-Dawood-1990a" TOTAL_1="32" TOTAL_2="32" VAR="3.9206349206349205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.02" MODIFIED="2009-05-04 12:02:56 +1200" MODIFIED_BY="Julie A Brown" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pain relief - descriptive data</NAME>
<TR>
<TH>
<P>Pain scale</P>
</TH>
<TH>
<P>TENS</P>
</TH>
<TH>
<P>Medical treatment</P>
</TH>
<TH>
<P>Conclusions</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.02.01" NO="1" STUDIES="1">
<NAME>Naproxen</NAME>
<OTHER_DATA ORDER="169" STUDY_ID="STD-Milsom-1994">
<TR>
<TD>
<P>Pain score 1-5 measured every 30min up to 240min - reported in graph form</P>
</TD>
<TD>
<P>High frequency high intensity TENS (unusual as usually low intensity)<BR/>n=12</P>
</TD>
<TD>
<P>One dose 500mg<BR/>n=12</P>
</TD>
<TD>
<P>No significant difference between the two treatments. Both groups had significantly reduced pain from baseline (p&lt;.0001, using the Student t-test)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="130.9147459983073" CI_START="5.456907590785663" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="26.728068975964955" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="2.1169885674446296" LOG_CI_START="0.7369465993481683" LOG_EFFECT_SIZE="1.426967583396399" METHOD="PETO" MODIFIED="2009-05-04 12:02:56 +1200" MODIFIED_BY="Julie A Brown" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="5.051801239593284E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="4.053217416888888">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Medical treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TENS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Medical</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.9147459983073" CI_START="5.456907590785663" DF="0.0" EFFECT_SIZE="26.728068975964955" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="2.1169885674446296" LOG_CI_START="0.7369465993481683" LOG_EFFECT_SIZE="1.426967583396399" NO="1" P_CHI2="1.0" P_Z="5.051801239593284E-5" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="4.053217416888888">
<NAME>Naproxen</NAME>
<DICH_DATA CI_END="130.9147459983073" CI_START="5.456907590785663" EFFECT_SIZE="26.728068975964955" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.1169885674446296" LOG_CI_START="0.7369465993481683" LOG_EFFECT_SIZE="1.426967583396399" ORDER="36466" O_E="5.0" SE="0.8106434833777776" STUDY_ID="STD-Milsom-1994" TOTAL_1="12" TOTAL_2="12" VAR="1.5217391304347825" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3691852411896992" CI_START="0.12122596024056086" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.1364622091158404" LOG_CI_START="-0.9164043671173651" LOG_EFFECT_SIZE="-0.3899710790007623" METHOD="MH" MODIFIED="2009-05-04 12:02:56 +1200" MODIFIED_BY="Julie A Brown" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.14652900113570982" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.451901479460438">
<NAME>Use of additional analgesics</NAME>
<GROUP_LABEL_1>HF TENS</GROUP_LABEL_1>
<GROUP_LABEL_2>Medical treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Medical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TENS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3691852411896992" CI_START="0.12122596024056086" DF="0.0" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.1364622091158404" LOG_CI_START="-0.9164043671173651" LOG_EFFECT_SIZE="-0.3899710790007623" NO="1" P_CHI2="1.0" P_Z="0.14652900113570982" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.451901479460438">
<NAME>Ibuprofen</NAME>
<DICH_DATA CI_END="1.3691852411896992" CI_START="0.12122596024056086" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.1364622091158404" LOG_CI_START="-0.9164043671173651" LOG_EFFECT_SIZE="-0.3899710790007623" ORDER="36467" O_E="0.0" SE="0.6184590386529916" STUDY_ID="STD-Dawood-1990a" TOTAL_1="32" TOTAL_2="32" VAR="0.3824915824915825" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-10 14:23:48 +1200" MODIFIED_BY="jane clarke">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-10 14:23:48 +1200" MODIFIED_BY="jane clarke" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADOCAMAAAAdQhu+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAISUlEQVR42u2d63KsKhCFPamp4uX6X16Vl6MqOzmJN+4Kjs6ofGvP
jspdFt2A0tJ1oDX81ykqoS2YD+qgOcA5nAM4B3AO4BzAOYBzcD48mrhLA9HOs7cHTfv6+FcQ5gfd
Tn8O4BzAOYBzAOfgrpxLdLIS7iWQVIYiArc7cC76rPWo46JqDen76fZRgkZJ+v07CppMjoPLLGhz
wFz4vwhiU3ZjJgONV05ucSiwgOoHVKKHKtbDqXYV6+CoB/f+vxswF3720F0YU1KB/CS1l83oriF2
Fzn/q0pJqFK9oGNT7nrBXy9EjHLVi1kJvO8g57I+UJP47K+d6PXwC27ZfGW5hYLnOddeLetMRUvo
PSpdXTT4Srnl1IroV08RWtPtveAMyl08OZMucYi8c+F91iQzKZQ1bVLUmsDGMdwv7b26HlS2vXIO
/chqqnYbMBneVQjiBOzygaYrm1sXhkK3L2EHO5ba6q0JvxN1hvfnP+oKlSGo6NPK+QXA2ihnbZR5
tHW/oOO9GpwDOAdwDu4AbBqaG7e3YtPwsVugq+IL3U5/DuAcwDmAcwDnAM67cQmLZJeyyHPrmmTF
D5uGN3BeYABx4LtxbBrertslslnIWiIEhguxrcMswYNvHF5YGLmCVzyHC80WcpYIXdpwwXOzJg+D
zUMcXmPT8B45twYQoTpfXfOcspHQOd+seQWLIF8v57Jp+FWQYqFtBJS/nvOsvcFmSwS9EB2C36/b
HQOIhDxKtYaQ9ehCKzjTGM6xZ1ixRIjsGiK3KXoqg2DMCDJoZK0z78+/VF1lAHT79fC9WyA4vwiw
aWimDwNwDuAczgFjuDvNzyEam4aDk/p3vhpgnwb6cwDnAM4BnAM4B3B+BESmBc3xl0DZp6EK15mf
9x+H1tNZ5OVTzkqZm+l2icwdPAck/DZyHkmyv+2D54CI34Nzn0tr7iBpB1T7rfrzQj0AmKuBu3Ce
2b4FMb9ffz733b6Fw+yAbs/jhjYNCboN789/bvv9diZqbcp5AqyNYp8Gxu0AzgGcAzgH1wY2Dc2N
27FpaAXfVAb9OYBzAOcAzgGcg6tyXrxIWEqi7JiaVKXIPg0ruOf8HJuGCs5l+LhqN/3tv8/cu4k9
naTpz3FYUO66jRUu0zf1E8l4UfRyajbEsPDVBskcoHodasbn7+9zOEy/2e0z9vbPlOumVpJxo3yu
puZm/pnIJsj0c76bGd1H8+icyghaQGJrBHdDhGohWtxXIeG8cJawVUuVSlv1Dvbtz4vGccXjO6lJ
d1zNPH/ce9LtYY8OduY8uUXKBum3Y67sWSb2OHSwB/Dk/LxgN4S8SBYLa2oiJpk5mvixY1d3Gwea
QK2cp7ZLcDw6R6VqGyrYSqH3SibjRekvvCiS8HKsF3ylHh2waVhD3Vrnq9YkWxN03+zTgJzfHayN
wqaBcTuAcwDnAM7BtYFNQ3PjdmwaWgE2DfTnAM4BnAM4B3AO2uR82kdhOUzsFF9Xrq9jn4Za7Dc/
X19OUbjiQj+fNTYNr9Tt/TYJMu2ZIK7YTTsopH0HLSDjv85JxkvU7scwXwn7NLxLzq2IjVJmhW04
0+5F5Dv8tCOdjrA64ef9GNyEOvZpeIucj1JZVN162XkwfEqH15mEQmMMVPtr+/NFO9LYCGHFHHUl
1FNjBzjfmf68NPtGCLpIG0Di2efneVGX1Kn413O3Hou6lOVMC3mtnAeWZIFVQ853soIOAwZXsZ2E
q8axaSjA1dY6y6bHACzjd20a2KcBOb8nWBuFTQPjdgDnAM4BnAM4B3AO4BzAOYDz42HeHP9cCSDn
yDmAc3A/8F6tFbT2Xu3Zhm2eFYwTJIBupz8HcA4Yw4E7DWgfrdzoMI4zf39Lx0NznP5YFdWOm9S2
vO24SxWXYPCypc5l2gjnZrjz/ldM+VRbarwqj+pNF7bkbaObrrQEJrjTbKb052vzu+2zJKN2a6y7
5vZojspqJsxm+k34YKA+b1VcAlV8w21xrszfzxSPWyfV/nusjdrNMTfmHaWzqQSpOI3Juerm3q5S
xW+Iqp7O+9kSpOM015/X1Jh5UjM/362o50cIcRzGcAWd6fb54V7zTJ7JbJ+fD+Pgsnt2Zse1UaMJ
/tYEVE3hU/PzRBzDc7j21Be6vT3AOZwDOAdwDuAcXA+P46b+4FxQCc6Zqd97Wo5upz8HcA7gHMA5
uMdcbWHWdpYRPQU7jPNQ+r/PWtyv0xTsP//yB90O4BxcgnOT7rcGR1PQ0UVhjLGuZq1/rC7ZCZ4k
Jwtm4ls2L66xYs5Vn19qaLK4GHPJukrlg6lbPPw3S5Wl3lZj9brd9K1tOgTuU0M0U5M2XlDjhjRB
480lXFHFUwqpoprXi74KChLJqxkLZYxVAsfX2KPiBtRkPGVt4GzLTRlWGeX7uNfKxjOBKd9gtLFt
Kff8i1LcxXxsY2P0a8AtoPHq4DU19lHTatWqFvozlOn/BwFUthNI6bqt5KT1pnrflDmtcFV4rhJe
B9bYY4MGne5Gld+4KhhlVCdc2p++cWywSV0dXWOPrcJUoSzHoCuWVsYxrt+JdOUlfCEcW2MfG+XH
LDTsoHGb4rGt2SSUiRmFKZlivlG7r1TOwTX22Kh3rEIZGc5rmDCoH1KZ2XPwMdUNN8jaTXEsqnov
6VFlOSU1r68xx3bJRgqtW77V2qj0kKFuwjV83n6adyzh83ZVel+71d5aQrP/Ht8QUgeQbu66Ns+r
LLPjbKKixvb45sAB/Nx3OaY66C4r0kpz/n3WGvs6a8F+LtTsHpeSMgq2B3iX2h7gHM4BnAM4B3AO
rgd3roYxcnOcY4qMbgdwDuAcwDmAcwDnAM4BAC/C/6hI5/Rn5pEzAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-08-10 14:23:48 +1200" MODIFIED_BY="jane clarke" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARMAAAG8CAIAAABygdbUAAATEklEQVR42u3dvY4dxdbG8S2REEww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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-05-05 12:57:09 +1200" MODIFIED_BY="Julie A Brown" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 High Frequency TENS vs Placebo, outcome: 1.1 Pain relief - overall experience.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArQAAADwCAMAAADGtge7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-05-05 12:57:57 +1200" MODIFIED_BY="Julie A Brown" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Low Frequency TENS vs Placebo, outcome: 2.1 Pain relief - overall experience.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArIAAAFQCAMAAAB0w22mAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-05-05 12:58:38 +1200" MODIFIED_BY="Julie A Brown" NO="5" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Low Frequency TENS vs Placebo, outcome: 2.2 Pain relief - 100pt VAS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvMAAADACAMAAAC+qhzPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-05-05 13:00:39 +1200" MODIFIED_BY="Julie A Brown" NO="6" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 High Frequency TENS vs Low Frequency TENS, outcome: 3.1 Pain relief - overall experience.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAroAAACQCAMAAADQizhSAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-05-05 13:01:12 +1200" MODIFIED_BY="Julie A Brown" NO="7" REF_ID="CMP-003.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 High Frequency TENS vs Low Frequency TENS, outcome: 3.2 Pain relief - 100pt VAS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwAAAACACAMAAACLB/75AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-05-05 13:03:04 +1200" MODIFIED_BY="Julie A Brown" NO="8" REF_ID="CMP-004.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 TENS vs Medical Treatment, outcome: 4.1 Pain relief - overall experience.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAADgCAMAAAAdbKEqAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-07-14 01:13:51 +1200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-05-04 13:43:13 +1200" MODIFIED_BY="Julie A Brown" NO="1">
<TITLE MODIFIED="2009-05-04 13:43:11 +1200" MODIFIED_BY="Julie A Brown">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-04 13:43:13 +1200" MODIFIED_BY="Julie A Brown">
<P>1 exp Menstruation disorders/ (21321)<BR/>2 Pelvic pain/ (2191)<BR/>3 (pelvic adj5 pain).tw. (4323)<BR/>4 Dysmenorrhea/ (2469)<BR/>5 dysmenorrh$.tw. (2884)<BR/>6 (painful adj5 menstrua$).tw. (110)<BR/>7 (painful adj5 period$).tw. (212)<BR/>8 menstrual disorder.tw. (78)<BR/>9 or/1-8 (26974)<BR/>10 Transcutaneous electric nerve stimulation/ (2524)<BR/>11 TENS.tw. (4211)<BR/>12 electric stimulation therapy/ or electroacupuncture/ (14755)<BR/>13 electrostimulat$.tw. (2455)<BR/>14 electrotherap$.tw. (795)<BR/>15 electric stimulat$.tw. (3097)<BR/>16 nerve stimulat$.tw. (14604)<BR/>17 electroanalges$.tw. (173)<BR/>18 or/10-17 (36843)<BR/>19 9 and 18 (136)<BR/>20 randomized controlled trial.pt. (263105)<BR/>21 controlled clinical trial.pt. (78151)<BR/>22 (randomized or randomised).ab. (207653)<BR/>23 placebo.ab. (108884)<BR/>24 drug therapy.fs. (1280145)<BR/>25 randomly.ab. (126866)<BR/>26 trial.ab. (181582)<BR/>27 groups.ab. (879682)<BR/>28 or/20-27 (2337353)<BR/>29 (animals not (humans and animals)).sh. (3235549)<BR/>30 28 not 29 (1980294)<BR/>31 30 and 19 (44)<BR/>32 limit 31 to yr="2001 - 2009" (26)<BR/>33 from 32 keep 1-26 (26)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-05-04 13:43:54 +1200" MODIFIED_BY="Julie A Brown" NO="2">
<TITLE MODIFIED="2009-05-04 13:43:28 +1200" MODIFIED_BY="Julie A Brown">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-04 13:43:54 +1200" MODIFIED_BY="Julie A Brown">
<P>1 exp Menstruation Disorder/ (23479)<BR/>2 Pelvis Pain Syndrome/ (4684)<BR/>3 Dysmenorrhea/ (3608)<BR/>4 menstru$ disorder$.ti,ab,hw,tn,mf. (3213)<BR/>5 (pelvi$ adj5 pain).ti,ab,hw,tn,mf. (6495)<BR/>6 (painful adj5 menstrua$).ti,ab,hw,tn,mf. (64)<BR/>7 (painful adj5 period$).ti,ab,hw,tn,mf. (165)<BR/>8 Dysmenorrh$.ti,ab,hw,tn,mf. (4038)<BR/>9 or/1-8 (29638)<BR/>10 nerve stimulation/ or electroacupuncture/ or transcutaneous nerve stimulation/ (19586)<BR/>11 electrostimulation therapy/ (3174)<BR/>12 TENS.ti,ab,hw,tn,mf. (3963)<BR/>13 electrostimulat$.ti,ab,hw,tn,mf. (32173)<BR/>14 electrotherap$.ti,ab,hw,tn,mf. (574)<BR/>15 electric stimulat$.ti,ab,hw,tn,mf. (1372)<BR/>16 nerve stimulat$.ti,ab,hw,tn,mf. (27444)<BR/>17 electroanalges$.ti,ab,hw,tn,mf. (155)<BR/>18 or/10-17 (60372)<BR/>19 9 and 18 (274)<BR/>20 Clinical Trial/ (531633)<BR/>21 Randomized Controlled Trial/ (165971)<BR/>22 exp randomization/ (26539)<BR/>23 Single Blind Procedure/ (7989)<BR/>24 Double Blind Procedure/ (71472)<BR/>25 Crossover Procedure/ (21005)<BR/>26 Placebo/ (123698)<BR/>27 Randomi?ed controlled trial$.tw. (32428)<BR/>28 Rct.tw. (2659)<BR/>29 random allocation.tw. (636)<BR/>30 randomly allocated.tw. (10126)<BR/>31 allocated randomly.tw. (1347)<BR/>32 (allocated adj2 random).tw. (559)<BR/>33 Single blind$.tw. (7418)<BR/>34 Double blind$.tw. (84352)<BR/>35 ((treble or triple) adj blind$).tw. (140)<BR/>36 placebo$.tw. (109416)<BR/>37 prospective study/ (80141)<BR/>38 or/20-37 (698900)<BR/>39 case study/ (5939)<BR/>40 case report.tw. (118491)<BR/>41 abstract report/ or letter/ (491476)<BR/>42 or/39-41 (613634)<BR/>43 38 not 42 (674549)<BR/>44 43 and 19 (105)<BR/>45 limit 44 to yr="2007 - 2009" (29)<BR/>46 from 45 keep 1-29 (29)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-07-14 01:13:39 +1200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-07-14 01:13:39 +1200" MODIFIED_BY="[Empty name]">Menstrual Disorders and Subfertility Group search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-04 13:45:20 +1200" MODIFIED_BY="Julie A Brown">
<P>Keywords CONTAINS "dysmenorrhea" or "Dysmenorrhea-Symptoms" or "dysmenorrhoea" or "pain-dysmenorrhea" or Title CONTAINS "dysmenorrhea" or "Dysmenorrhea-Symptoms" or "dysmenorrhoea" or "pain-dysmenorrhea"</P>
<P>AND</P>
<P>Keywords CONTAINS "TENS" or "TENS study" or "electro-acupuncture" or "electro-magnetic" or "electroacupuncture" or "electrical activation" or "Transcutaneous Electric Nerve Stimulation" or Title CONTAINS "TENS" or "TENS study" or "electro-acupuncture" or "electro-magnetic" or "electroacupuncture" or "electrical activation" or "Transcutaneous Electric Nerve Stimulation"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-05-04 13:46:02 +1200" MODIFIED_BY="Julie A Brown" NO="4">
<TITLE MODIFIED="2009-05-04 13:46:00 +1200" MODIFIED_BY="Julie A Brown">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-04 13:46:02 +1200" MODIFIED_BY="Julie A Brown">
<P>1 exp Menstruation disorders/ (1067)<BR/>2 Pelvic pain/ (157)<BR/>3 (pelvic adj5 pain).tw. (364)<BR/>4 Dysmenorrhea/ (259)<BR/>5 dysmenorrh$.tw. (517)<BR/>6 (painful adj5 menstrua$).tw. (10)<BR/>7 (painful adj5 period$).tw. (38)<BR/>8 menstrual disorder.tw. (8)<BR/>9 or/1-8 (1699)<BR/>10 Transcutaneous electric nerve stimulation/ (437)<BR/>11 TENS.tw. (450)<BR/>12 electric stimulation therapy/ or electroacupuncture/ (1013)<BR/>13 electrostimulat$.tw. (166)<BR/>14 electrotherap$.tw. (115)<BR/>15 electric stimulat$.tw. (141)<BR/>16 nerve stimulat$.tw. (1108)<BR/>17 electroanalges$.tw. (14)<BR/>18 or/10-17 (2429)<BR/>19 9 and 18 (23)<BR/>20 limit 19 to yr="2001 - 2008" (9)<BR/>21 from 20 keep 1-9 (9)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-05-04 13:46:30 +1200" MODIFIED_BY="Julie A Brown" NO="5">
<TITLE MODIFIED="2009-05-04 13:46:28 +1200" MODIFIED_BY="Julie A Brown">AMED search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-04 13:46:30 +1200" MODIFIED_BY="Julie A Brown">
<P>1 exp Menstruation disorders/ (348)<BR/>2 Pelvic pain/ (0)<BR/>3 (pelvic adj5 pain).tw. (148)<BR/>4 Dysmenorrhea/ (71)<BR/>5 dysmenorrh$.tw. (125)<BR/>6 (painful adj5 menstrua$).tw. (4)<BR/>7 (painful adj5 period$).tw. (11)<BR/>8 menstrual disorder.tw. (1)<BR/>9 or/1-8 (541)<BR/>10 Transcutaneous electric nerve stimulation/ (543)<BR/>11 TENS.tw. (325)<BR/>12 electric stimulation therapy/ or electroacupuncture/ (637)<BR/>13 electrostimulat$.tw. (89)<BR/>14 electrotherap$.tw. (879)<BR/>15 electric stimulat$.tw. (1569)<BR/>16 nerve stimulat$.tw. (743)<BR/>17 electroanalges$.tw. (8)<BR/>18 or/10-17 (3596)<BR/>19 9 and 18 (7)<BR/>20 limit 19 to yr="2001 - 2008" (2)<BR/>21 from 20 keep 1-2 (2)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2009-07-14 01:13:51 +1200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-07-14 01:13:51 +1200" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-04 13:47:06 +1200" MODIFIED_BY="Julie A Brown">
<P>1 exp Menstruation disorders/ (0)<BR/>2 Pelvic pain/ (0)<BR/>3 (pelvic adj5 pain).tw. (279)<BR/>4 Dysmenorrhea/ (136)<BR/>5 dysmenorrh$.tw. (248)<BR/>6 (painful adj5 menstrua$).tw. (20)<BR/>7 (painful adj5 period$).tw. (40)<BR/>8 menstrual disorder.tw. (15)<BR/>9 or/1-8 (588)<BR/>10 Transcutaneous electric nerve stimulation/ (0)<BR/>11 TENS.tw. (492)<BR/>12 electric stimulation therapy/ or electroacupuncture/ (0)<BR/>13 electrostimulat$.tw. (208)<BR/>14 electrotherap$.tw. (110)<BR/>15 electric stimulat$.tw. (447)<BR/>16 nerve stimulat$.tw. (1215)<BR/>17 electroanalges$.tw. (12)<BR/>18 or/10-17 (2337)<BR/>19 9 and 18 (3)<BR/>20 limit 19 to yr="2001 - 2008" (2)<BR/>21 from 20 keep 1-2 (2)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>